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Symbols and abbreviations 
 
1A Molecule singlet excited state 
1O2 Singlet-oxygen 
3A Molecule triplet excited state 
A Absorption 
A Acceptor 
A* Excited molecule 
ACLFX Acyl Lomefloxacin 
AcOH Acetic acid 
Aem Absorbance at emission wavelength 
Aex Absorbance at excitation wavelength 
BIO Biomolecule 
BZ Benzene 




CLL Chronic Lymphocytic Leukemia 
CR Cross relaxation 
CSU Cooperative sensitization upconversion 
D Donor 
DCO Deacetyl-colchicine 
DMEM Dulbecco’s Modified Eagle Medium 
DMF Dimethylformamide  
DNA Deoxyribonucleic acid 
EDS Energy Dispersive Spectroscopy 
Eox Oxidation potential 
Ered Reduction potential 
Es Singlet Energy 
 
 
Symbols and abbreviations 
ESA Exited-state absorption 
ESI Electrospray ionization 
EtOAc Ethyl Acetate 
ETU Energy transfer upconversion 
FBS Fetal Bovine Serum 
Fcorr Corrected fluorescence 
Fl Fluorescence 
FLX Fleroxacin 
Fobs Observed fluorescence 
FQ fluoroquinolone 
FQ(-F-) Aryl carbene 
FQ(-F)¨+ Diradical anion 
FQ(-F)+ Aryl cation 
HSA Human Serum Albumin 
HPLC High Performance Liquid Chromatography  
hν Photon 
IC Internal Conversion 
IC50 Inhibitory concentration 
ICT Intramolecular Charge Transfer 
IFE Inner Filter Effect 
ISC Intersystem Crossing 
Ka Association constant 
Kd Diffusion rate constant 
Kq Quenching rate constant 
Ksv Stern-Volmer constant 
LFP Laser Flash Photolysis 
LFX Lomefloxacin 
Ln3+ Trivalent ions of Lanthanides 
MeOH Methanol 
NIR Near Infrared 
NMR Nuclear Magnetic Resonance 
NRU Neutral Red Uptake 
 
 
Symbols and abbreviations 
OA Oleic acid 
ODE Octadecene 
PA Photon avalanche 
PAA Poly acrylic acid 
PB Phosphate buffer 
PBS Saline Phosphate Buffer 




PMT Photomultiplier Tube 
PPG Photolabile photoprotecting group 
PTFE Polytetrafluoroethylene  
PTT Photothermic therapy 
Q Quencher 
ROS Reactive Oxygen Species 
SA Succinic acid 
SD Standard deviation 
SDS Sodium dodecyl sulphate 
TEM Transmission electron microscopy 
TICT Twisted Intramolecular Charge Transfer 
Trp Triptophan 
UC Upconversion 
UCNP Upconversion nanoparticle 
UV Ultraviolet 
UVA Ultraviolet A 
UVB Ultraviolet B 
UVC Ultraviolet C 
UV-Vis ultraviolet-visible 
ΔAbsorbance Absorbance variation 
ΔGpet Gibbs free energy 
λmax maximum wavelength  
 
 
Symbols and abbreviations 
τ Lifetime 
τ0 Transient species lifetime 
τFl Fluorescence lifetime 
ϕD Photodegradation quantum yield 
ϕFl Fluorescence quantum yield 
ϕPF Photoproduct formation yield 
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1.1. Basic concepts on photochemistry and photophysics 
Molecular photochemistry is defined as the science related to the 
description of physical and chemical processes derived by photons 
absorption. A photochemical process starts with radiation absorption 
of chromophore groups (whose electrons are in n or pi orbital such as 
carbonyl or aromatic groups) inside a molecule. The absorption and 
emission spectra of a molecule give relevant information about the 
structure, energy, and dynamics of its electronic excited states. Its 
study may help in the comprehension and interpretation of 
photochemical reactivity and their photophysical properties.  
A molecule, after the absorption of a photon, rises to an electronic 
excited state. This virtual state is unstable compared with the ground 
state. If the excited molecule does not change its structure, it will look 
for a way to lose the energy giving place to a photophysical process. 
The different processes which can occur can be grouped in two: 
photochemical and photophysical. 1 
Photochemical processes are the transformations that a molecule 
can suffer from its electronic excited state to give place to different 
structures related to its constitution or configuration compared with 
the ground state one.  
Photophysical processes produce a change in the quantum state of 
the molecule with no transformation in its natural chemistry. They are 






ground state are produced. These processes can be radiant or non-
radiant. A radiant process implies the emission of an electromagnetic 
radiation from the electronic excited state to the ground state. On the 
other hand, in a non-radiant process, the energy is transferred to 
another state without any emission.  
The most common radiant processes are: 
− Absorption: it is characterized by a molar absorption coefficient 
(related to the incidence area of the chromophore and the 
probability to produce an absorption in a specific wavelength). The 
absorption is associated to electronic transitions between different 
energetic levels in specific groups of the molecule. They can be 
permitted transitions (singlet-singlet) or forbidden ones (singlet-
triplet) by the spin rule.  
− Fluorescence: emission permitted by the spin rule in which a 
deactivation of an excited specie from first singlet excited state to 
ground state with the emission of a photon of radiation.  
− Phosphorescence: forbidden by spin rule. On it, a deactivation of an 
excited specie from the first triplet excited state to the ground state 
occurs with a photon emission.  
Between the most common non-radiant processes are: 
− Internal conversion (IC): permitted transitions between excited 
states of the same multiplicity. On it, the excited molecule goes to a 






relaxations without radiation emission. It is favored when the 
electronic states are of similar energy.  
− Intersystem crossing (ISC): forbidden transitions between states of 
different multiplicity. As in the internal conversion, the probability 
of this transition is higher if the vibrational levels of both are 
overlapping.  
− Vibrational relaxation: transmission of an excess of energy of a 
vibrational excited level to a lower energy vibrational level.  
These processes are shown in the Jablonski diagram (Scheme 1.1). 
Their duration is shown in table 1.1. 




PHOTOPHYSICAL PROCESS TIME (s) 
Absorption 10-15 
Vibrational relaxation 10-12-10-10 
Singlet excited state (S1) lifetime 10-10-10-7 
Internal conversion 10-11-10-9 
Intersystem crossing 10-10-10-8 







Scheme 1.1. Simplified Jablonski diagram 
Narrow variations in the position and intensity of the band are 
related with structural changes. The study of these fluctuations helps 
to understand and determine the photophysical properties and the 
correlation between the structural characteristics and the damage 
caused in a biological environment. 
Otherwise, when two chromophores are present in the same media 
(covalent bonded or not), light-induced processes can occur between 
them, such as energy transfer, electronic transfer, exciplex formation, 
proton transfer or excimer formation.  
1.1.1. Photoinduced energy transfer 
The energy of a donor chromophore (D*) in its excited state is 
transferred to an acceptor chromophore (A). In that moment, the 
deactivation of the donor (D) to the ground state and excitation of the 






For this process to occur, the energy of the excited state of the 
donor may be higher than the acceptor one (Eq 1.1). In addition, the 
donor needs a higher enough lifetime to react.  
ΔG = E*D – E*A     Eq. 1.1 
where ΔG is the variation of the free Gibbs energy of the process; E*D 
is the energy of the donor excited state and E*A the acceptor excited 
state energy. 2 
1.1.2. Photoinduced electron transfer 
Usually, an electron transfer process takes place when a molecule in 
its excited state gives an electron to other molecule in the ground state.  
The thermodynamics of this processes can be determined by the 
Rehm-Weller equation (equation 1.2). 
ΔG = Eox – Ered – E0-0 + C   Eq. 1.2 
where ΔG is the variation in the Gibbs free energy of the process, Eox 
and Ered are the oxidation and reduction potential respectively in the 
ground state of donor and acceptor, E0-0 is the energy of the involved 
excited state and C is the coulombic term which considers the 







Scheme 1.6. Electron transfer mechanism 
1.2. Cancer treatments nowadays 
Cancer is among the leading causes of deaths worldwide4 and it is 
mainly associated with ageing of population and lifestyle.5 Over the 
next 20 years, the number of new cases is projected to increase by 
about 70%.6 Surgery, radiotherapy and chemotherapy are the most 
common types of treatments available nowadays. The use of 
chemotherapy for treating cancer began in the 1930s. Discovered and 
named by Paul Ehrlich, a German scientist with particular interest in 
alkylating agents. From World War II, nitrogen mustard began to be 
used as the first chemotherapy after the exposure of soldiers to it 
showed decreased levels of leukocytes.7 A reduction in the 
electrophilicity was necessary in order to reduce its toxicity. First of all, 
aliphatic mustards were developed and then, in the 1950s alkylating 
drugs appear providing a slower reactivity with the DNA. In 1953 
Chlorambucil was synthesized by Everett et al. It is a bifunctional 
alkylating agent with activity against human neoplastic diseases. 
Chlorambucil is still used in several cancer such as Chronic lymphocytic 






that time, monotherapy drugs only achieved brief responses in some 
types of cancer.8 
The beginning of the 20th century had a major limitation in the drug 
discovery. It was the development of models able to discern which 
chemicals have anticancer activity in humans.9 
In the 1960s surgery and radiotherapy were the basis for solid 
tumour treatment but this leads in a curability plateau due to 
uncontrolled micrometastases. Adjuvant therapies arise as the first 
multimodality treatment with the combination of chemotherapy with 
radiotherapy or surgery. This strategy is still used today for numerous 
types of tumours.7  
The quick development in the 1970s of the understanding of 
molecular changes in cancer cells increased the number of drugs with 
different mechanisms of action during the 1980s. This knowledge led 
to liposomal therapies to reduce side effects such as cardiotoxicity. 
With this technique the drug is placed inside vesicles made of lipid 







Another used strategy has been the use of drugs which were 
designed for other purposes such as antibacterial agents. Two of them 
have been studied in this thesis. The first one is the colchicine. It is an 
alkaloid compound that can be found most abundantly in Colchicum 
autumnale. Since Egyptian times it has been used to treat gouty 
arthritis. Due to its side effects and high toxicity, it is not until 2009 
when FDA approved it controlling strictly the dose.   
The other ones are fluoroquinolones. They arise from the widely 
studied family of the quinolones. They were usually used as 
antibacterial agents and tuberculosis treatment.  
As shown, massive efforts have been made to understand the 
cancer biology, but it has been slowly translated into significant 
improvements in cancer care.10 Lack of water solubility, nonspecific 
biodistribution and targeting, poor oral bioability and toxic side effects 
among others are the major limitations of conventional drug delivery 
systems. That is the reason why new types of treatment are emerging.  
One example of new treatment is the immunotherapy which is 
based on the use of immune system components such as antibodies, 






dendritic cells… to treat diseases. It is not only used for cancer but also 
allergies or autoimmune diseases among others.7 The aim of 
immunotherapy in cancer is to kill tumour cells or give the immune 
system the power to destroy tumours. Immunotherapy drugs have 
been approved; however, they are not widely used as chemotherapy, 
radiotherapy, or surgery.  
Other treatments which are arising nowadays are targeted therapy 
(based on small-molecule drugs or monoclonal antibodies), hormone 
therapy (can be used as neo-adjuvant and/or adjuvant therapy) and 
stem cell transplant (restoring blood-forming stem cells after certain 
cancer treatments).11 
Another example of cancer treatment still growing is nanomedicine. 
It is based on nanoscale materials providing the opportunity to reduce 
the mentioned side effects of nowadays treatments.11 This treatment 
includes a great variety of techniques that will be explained in detail in 
the next section.  
Since the beginning of the history of medicine, light has been used 
as a way of treatment. It has to do with the extraordinary connection 
between light and biology. Plants are a clear example of that relation 
with their sophisticated energy-harvesting machinery able to convert 
solar energy into chemical energy. That is the reason why light has 
played an important role since the very beginning of the medicine. And 






new drugs and with new techniques such as light induced controlled 
drug delivery.  
1.3. Nanomedicine  
Nanotechnology can be defined as the use of materials between 1 
and 100 nm.12 When nanomaterials are applied in medicine it is known 
as nanomedicine and involves the use of engineered materials in the 
nanoscale to develop new treatments.  
Main characteristics of nanocarriers are their high surface-to-
volume ratio, better reach to tumour tissue and controlled drug 
release.10 Nanoparticles may reduce problems related to poor water 
solubility and stability of drugs by caging them into a hydrophilic 
nanocarrier. Besides, better biodistribution and targeting are achieved 
by constructing specific nanocompounds.13 In addition, biodegradation 
or excretion of the drug may be avoided by encapsulation. Finally, 
tumour resistance can be reduced due to targeted nanocarriers.14 
An extensive range of nanomaterials have been developed as 
therapeutics either for cancer or other diseases. In agreement with the 
registry made by clinicaltrials.gov, a total of 1239 nanomedicine 
formulations have been registered as treatments by January 2020. As 
many as 939 of these are in the field of cancer therapy.15 






Natural mechanism of action of viruses is based on host’s immune 
system invasion to ensure their own reproduction.16 Taking advantage 
of this statement, virus-like nanoparticles have emerged as a new 
immunotherapy tool able to express therapeutic proteins.17 In 
comparison to synthetic nanoparticles they are biocompatible and can 
be produced in large quantities in a very cheap manner. Plant-virus 
based nanoparticles have been the focus of researchers trying to 
minimize the chance of the virus to be infectious.18 In addition, they can 
be used as reaction container or drug capsule because of their self-
assemble property.19,20 The main challenge is to evade the immune 
system response  
1.3.2. Organic nanoparticles 
At the present, natural or synthetic compounds are considered as 
organic nanocarriers.10 There are many different types of organic 
nanocarriers, some of which will be described here.  
1.3.2.1. Drug conjugates 
Considered nowadays as one of the most successful nanomedicine 
therapeutics in clinical cancer. Their nanometric size and their 
conjugation to active pharmaceutical ingredients are the main reasons 
to consider drug conjugates as nanotherapeutics.21,22  






Liposome-based nanoparticles are created when an amphiphilic 
lipid is added to a hydrophilic liquid via lipid bilayers obtaining a 
spherical particle around 50 to 500 nm.4 An advantage of these 
materials is the possibility to carry molecules which usually have 
problems like lack of hydrophilicity or negative charges.23 In addition, 
they can respond to different stimuli such as pH, enzymes, 
temperature, or light. Molecules can be loaded in the aqueous area or 
in the middle of the lipid layer depending on its polarity changing the 
pharmacokinetics of the drug and reducing its side effects.4  
1.3.2.3. Polymer-based nanocarriers 
Polymeric nanoparticles can be prepared from synthetic or natural 
polymers.10 They are usually spherical and solid. Many different drugs 
can be loaded in this type of nanoparticles, e.g., peptides, vaccines, or 
hydrophilic and hydrophobic drugs.23 One of their main advantages is 
that they provide stability to labile molecules such as proteins.24 
1.3.3. Inorganic nanoparticles 
Different materials are included under this category. Gold and silver 
nanoparticles have special applications in surface plasmon resonance 
analysis. Gold nanoparticles serve as drug release material controlled 







Silica and porous silica nanoparticles have been studied for different 
applications such as therapy, diagnostic and drug delivery.27,28  
Quantum dots are metallic particles made of semiconductor atoms 
like CdSe, ZnO or GaAs among others. Thanks to their optical 
characteristics they are good option for biomedical diagnostics and 
imaging.29,30  
 
Figure 1.2. Examples of some nanocarriers 
1.4. Upconversion nanoparticles 
Upconversion nanoparticles (UCNP) are generally composed by an 
inorganic matrix with appropriated dielectric host lattice (e.g., NaYF4) 
and optical inert lanthanides (e.g., Y), and doped with trivalent rare-
earth ions (Ln3+, e.g., Yb3+, Er3+, Tm3+) achieving unique luminescent 
characteristics. They are usually codoped with a Ln3+ able to absorb light 
(sensitizer) and another one which emits light (activator).31–33 It is 
known as anti-Stokes process in which two or more low energy photons 






emitting a higher energy photon (UV-Visible range).34,35 The main 
characteristic is that those photons are absorbed by real energy states 
compared with the virtual energy states needed in Quantum dots or 
other nanoparticles.36 In addition, the shielding of the intra f-f electron 
transitions by outer complete 5s and 5p electron shells provides high 
resistance to both photobleaching and photochemical degradation.37,38 
The electronic configuration of each lanthanide is unique and it is 
usually insensitive to inorganic host lattice, nanoparticle size and shape. 
It can be traduced into a system of well-defined, ladder-like energy 
levels.33,38  
Thanks to their unique optic properties like high relation 
signal/noise, low toxicity and higher penetration in tissues, UCNP are 
gaining importance for biomedical applications such as photodynamic 
therapy, bioimaging39 or controlled drug release40 and in other areas 
away from medicine like laser design, sensors41 or solar cells. 42–46  
1.4.1. Upconversion processes 
Upconversion processes are a great method to produce visible light 
after NIR excitation. Trivalent ions of lanthanides (Ln3+) have unique 
properties thanks to which these types of emission are possible. Ln3+ 
ions have their 4f electronic orbitals partially full (4fn5s25p6, n= 0-14). 
The coupling of the electrons in 4fn orbitals with electrons of the 
completed orbitals 5s2 and 5p6 results in 4f-4f transitions. If the ions are 







Several pathways are possible for the UC emission, after sequential 
absorption of two or more photons in NIR, due to great number of 
energetic levels of the lanthanides.  
There are five basic upconversion mechanisms encompassing 
excited-state absorption (ESA), energy transfer upconversion (ETU), 
photon avalanche (PA), cooperative sensitization upconversion (CSU) 
and cross relaxation (CR), although ETU is the most competitive for 
UCNP processes.37,47–51 Those three are discussed below. 
1.4.1.1. Excited-state absorption (ESA) 
High photon density, low ion concentration, avoiding cross 
relaxation, and large absorption efficient section are needed to 
facilitate ESA process.31 A single ion with multiple energy levels is able 
to absorb two successive photons due to the ladder-like structure of 
the system (see Figure 1.3). First of all, a photon is absorbed and a 
transition from ground state (G) to the intermediate exited state (E1) 
takes place. A second photon can be absorbed occurring the transition 
between E1 to a more energetic excited state (E2). The emission takes 
place with the relaxation from E2 to F.52 An efficient ESA is achieved 
only when a ladder-like structure of the energy states exists. Only a few 







Figure 1.3. Principal UC emission processes for lanthanide-doped UCNP: 
exited-state absorption (ESA), energy transfer upconversion (ETU), photon 
avalanche (PA). Yb3+ activator and Ln3+ sensitizer. Excitation (continuous line), 
energy transfer (dashed line) and emission (red dashed line). 
1.4.1.2. Energy transfer upconversion (ETU) 
ETU is considered the most efficient upconversion process and the 
most observed in UCNP. It involves two neighboring lanthanide ions 
Ln3+ which are known as sensitizer an activator (see Figure 1.3). The 
absorption effective section of the sensitizer needs to be higher than 
that of the activator. Both, sensitizer and activator can absorb a photon 
thereby promoting their respective excited states (E’ and E1, 
respectively). The sensitizer successively transfers its energy by non-
radiative process to the activator, relaxing to its ground-state F’.  The 
activator reaches its upper excited state E2 from which emission due to 
transition E2 → F occurs. This process is highly dependent on the 
distance between ions.38,53 






Photon avalanche is an UC which needs high excitation power to 
occur. The process starts with population of level E1 by non-resonant 
GSA, followed by resonant ESA to populate the higher energy level E2. 
Cross-relaxation energy transfer between the excited state and F’ of the 
neighbor ion results in the population of E1. Both ions easily populate 
E2 to further initiate cross-relaxation and exponentially increase level E2 
population by ESA, producing strong UC emission as an avalanche 
process.37,54 PA usually occurs in systems with high dopant 
concentration and enormous excitation power where the intermediate 
energy levels act as energy reservoir.38,54,55 
UCNP nowadays are mostly based on ETU due to their higher 
efficiency. As previously discussed, this process needs an activator and 
a sensitizer. In this case, the most studied ones will be shown, with Yb3+ 
as an activator and Er3+ or Tm3+as sensitizers.31 
On one hand, in a matrix doped with Yb and Er, emissions in the 
violet (415 nm), the green (525nm, 2H11 → 4I15/2 and 542 nm, 2S1/2 → 
4I15/2) and the red (655 nm, 4F9/2 → 4I15/2) (see Figure 1.4) are observed. 
In the case of the emission in green and red the processes are 
biphotonic and for violet it is attributed to a triphotonic process. On the 
other hand, a matrix doped with Yb and Tm shows emission in UV (362 
nm), visible (450, 475 and 644 nm) and NIR (800 nm). In this case the 
UC emission involves more than two photons due to their higher 
distance between energetic levels (see Figure 1.4). In the case of the 






nm (1G4 → 3F4) emissions require four photons. For those at 475 (1G4 
→ 3H6) and 644 nm (1G4 → 3F4), 3 photons are needed and, for the 
emission at 800 nm (3H4 → 3H6), only two.31 
 
Figure 1.4. Scheme of ETU mechanisms in a matrix doped with Yb/Er or Yb/Tm. 
Colored arrows correspond to the emission. Dashed arrows represent transfer 
energy process or relaxation. Black continuous arrows mean excitation 
process.  
1.4.2. UCNP composition 
As previously mentioned, 4f-4f transitions are partially permitted 
when lanthanides are in a crystalline matrix.56 Different hosts have 
different coordination number and distances between dopants and, 






The organic matrix should be selected depending on the desired 
optical properties and different parameters must be considered: a) 
transparency of the matrix in the spectral range of interest, b) high 
optical damage threshold, c) great chemical and thermal stability, d) 
high tolerance to Ln3+ luminescent and e) low phonon energy to 
prevent movement generated by the oscillation of the crystal lattice 
thus reducing non-radiative relaxation of the Ln3+ luminescent centers 
and maximizing the radiative emission.31,38,54 
Different materials have been studied as matrix like vanadates (e.g. 
YVO4, phonon energy 890 cm-1)57, oxides (e.g., Y2O3, phonon energy 
550 cm-1)58, fluorides (e.g., NaYF4 phonon energy 350 cm-1)59 or 
heavy halides like chlorides, bromides or iodides (phonon energy less 
than 300 cm-1). An advantage of the oxides is their high chemical 
stability but they have high phonon energy. In contrast, heavy halides 
have low phonon energy but they are hygroscopic and are use-
limited.54 That is the reason why fluoride materials are the most used 
as matrix, in particular NaYF4. At the same time, the crystal field of the 
matrix has a strong influence on the optical properties.38 NaYF4 matrix 
has two different crystalline phases, hexagonal and cubic. The cubic 
phase (α-NaYF4) is less thermodynamically stable than the hexagonal 






1.4.3. UCNP synthesis 
The design of synthetic routs for the obtention of UCNP is crucial to 
control the form, size, composition, and crystalline phase. To obtain 
small size distribution, best strategy is bottom up. There are different 
methods but all of them are made with colloidal solutions which allow 
the control of size and shape of the nanoparticles. 
Several methods are established for the bottom-up strategy like 
coprecipitation, hydro(solvo)thermal, thermal decomposition, 
Ostwald-Ripening among others.38,54,55,60 
Due to the large number of existing UCNPs, only the NaYF4 matrix 
and the synthesis methods most used today will be explained.  
1.4.3.1. Coprecipitation 
Yi et al. 61 were the first to use this method which is one of the 
easiest procedures to obtain monodispersed NPs. At the beginning, 
UCNP were obtained with a shell of ethylendiaminotetraacetic (EDTA). 
The control of the size is difficult with this covering, so other coverings 
like polyethyleneimine (PEI) or polivinylpirrolidone (PVP) have been 
proposed 62 
Even so, UCNP obtained by coprecipitation have low luminescence 
and they also need high temperatures (400-600°C) to obtain β phase.61 






This method is about the use of organometallic precursors of the 
lanthanides, like trifluoroacetates, achieving high temperatures ( 
300°C) with octadecene (ODE) as organic solvent with high boiling point 
and oleic acid (OA) as organic ligand.63 
With this method, high crystallinity, monodispersed, and high 
luminescent UCNP are obtained.54 
1.4.3.3. Hydro(solvo)thermal 
In this method lower temperatures are needed (> 250°C) but in 
contrast, pressure needs to be high. To achieve these conditions an 
autoclave is necessary. The method starts from nitrates (Ln(NO3)3 
precursors in polar solvents. In this case, the F- source is NH4F2. The 
duration of the synthesis goes from 12 to 24 h depending on the 
desired size. One of the main advantages of this method is that there 
are no toxic subproducts produced during the process. With the change 
of the surfactant, the solvent or the reaction time it is possible to 
control the size of the UCNPs.64 
1.4.3.4. Ostwald-ripening  
The beginning of this synthesis is LnCl3 with OA as ligand and ODE as 
solvent.65 The controlled addition of a solution with stoichiometric 
quantities of sodium and fluor allows the formation of nucleus of NaYF4 
stabilized by OA. Afterwards, an increase of the temperature until  







Figure 1.5. Growth stages of β-NaYF4:Yb3+/Tm3+. 
The particles with less surface/volume ratio (that is the bigger ones) 
are energetically favored over the smaller nanoparticles (less stable).67 
This is known as Ostwald ripening process.  
Drop by drop addition of fluor and sodium precursors allows the 
spatial separation of the nucleation and the crystal growth.68 The 
control of the temperature and reaction time, in addition to the 
variation of the OA/ODE ratio allow the obtention of monodisperse β 
phase crystalline nanoparticles with different sizes (Figure 1.5).65 
This method does not generate toxic subproducts, it needs shorter 
reaction time and milder reaction conditions.69 In conclusion, it is 
considered as the best procedure to obtain monodispersed UCNP with 
uniform size and one crystalline phase.70 For all these reasons, the 
Ostwald ripening method is the selected for the development of this 
thesis.  
1.4.4. UCNP biomedical applications 
1.4.4.1. Bioimage  
The visualization of biological samples to obtain information about 






biomedicine. It leads to earlier detection and screening of diseases.71 
As mentioned before, NIR light has higher penetration into tissues and, 
moreover, it prevents the autofluorescence of the samples and the light 
scattering.44,72 In addition, NIR light has excellent optical and chemical 
properties. All these characteristics make UCNP a great alternative for 
UV-visible fluorophores and quantum dots.71,73 Despite these 
advantages, overcoming the high excitation density required for UCNP 
processes is costly and limits its applications.71,74 
Due to the great variety of UCNP, they can be applied in a vast 
number of bioimaging techniques such as fluorescence, ultrasounds or 
X-ray among others.31,45,72,75 
1.4.4.2. Biosensing and bioassay 
Detection of different molecular targets or biomolecules play a key 
role in monitoring physiological processes which are fundamental and 
play vital roles. The main advantage of UCNP systems for biosensing is 
the high sensitivity at deep locations.76 UCNP are not used by 
themselves, apart from temperature sensing, because they need to be 
combined with recognition elements such as an antibody or an enzyme. 
The UCNP act as the transducer of the recognition into an optical 
signal.43 There are different types of biosensing: 
- Temperature sensing.77 







- Ions sensing like mercury. 78 
- Biomolecules  detection or bioassays76 
1.4.4.3. Therapy 
UCNP are useful as therapeutic agents, in special against cancer. 
There are different types of treatment with these nanoparticles: 
- Photodynamic therapy (PDT): consists in the generation of reactive 
oxygen species (ROS) through photosensitizer activation by light. 
Different organic molecules as for example methylene blue or 
chlorin e6 are able to generate ROS, more specifically singlet 
oxygen, after NIR excitation.79 
- Photothermic therapy (PTT): UCNP functionalized with 
photothermic agents like gold or silver nanoparticles. The 
temperature increase causes cell damage.80 
- The chemotherapy based on UCNP has two different aspects: the 
bioimage guided therapy and the controlled drug delivery by light.81 
1.5. Drugs for photosensitized reactions 
The exposure of a patient to solar light during a treatment with 
some drugs can produce a phototoxic reaction which will be presented 
as an erythema. Some examples of photosensitizing drugs are 
antibiotics such as tetracyclines or fluoroquinolones, nonsteroidal anti-
inflammatory drugs like ibuprofen or targeted therapies such as 
Imatinib, among others. Those photosensitizing properties can be used 






There are two types of principal photosensitized reactions. The first 
one is the photoallergy. It occurs as a result of an immune system 
response to an antigen produced in the skin after exposure of a 
photosensitizing substance to solar radiation. It only occurs in some 
people.82 On the other hand, phototoxicity can occur which, will be 
produced in every person who receives a chemical substance in 
sufficient dose and appropriate radiation exposure. This last type of 
photosensitization can be used as therapeutic strategy and is going to 
be explained below.  
1.5.1. Photosensitization mechanism 
The transitory species generated by the interaction light-drug 
(singlet and triplet excited states as well as intermediate reagents) can 
react with biomolecules through two different mechanisms 83: 
i. Type I: the excited states or intermediate reagents of the drug can 
generate charge, hydrogen or energy transfer processes with 
biomolecules bringing about different types of lesions.  
ii. Type II: an energy transfer from excited state of the drug to the 
molecular oxygen occurs, generating singlet oxygen (1O2). This 
oxidant reagent reacts with numerous biological molecules. It only 
will occur when the energy of the excited state is greater than that 








The solar radiation which reaches the earth is composed of 
wavelengths comprised between 290 and 5000 nm. The stratospheric 
ozone layer blocks the most dangerous wavelengths (UV-C). The 
radiation energy is composed by 56% of infrared rays (800-5000 nm), 
39% of visible light (400 nm – 800 nm) and 5% of ultraviolet radiation 
(UV) (290 nm – 400 nm). The latter is divided in: 
i. UVA (320 nm – 400 nm) which constitutes 98% of the UV rays that 
penetrate glass and epidermis.  
ii. UVB (290 nm – 320 nm) represents 2% of UV rays and are blocked 
by glass and epidermis. 
iii. UVC (100 nm – 290 nm) is absorbed by the ozone layer and does not 
reach the earth. 84  
Proteins and nucleic acids are able to absorb UVB light directly. 
However, UVA can result dangerous when photosensitizing molecules 
are present. They are able to modify molecules.  
Ultraviolet light has several drawbacks that make it not the best 
option for non-skin treatments. Its greatest limitation is the low 
penetration into the tissues. This is due to the scattering absorption of 
UV light by water and biological substances.85 Taking this drawback into 
account, treatments that require light on internal tissues will not be 
possible with UV light. In contrast, near-infrared light (NIR) can 








Fluoroquinolones are part of a big family known as quinolones. They 
are synthetic antimicrobial compounds with bactericidal action that 
first appeared in 1962. Quinolones have a basic structure, 4-quinolin 
acid, 3-carboxilic (4-quinolone).86 The low number of bacteria on which 
they could act at the beginning drove the synthesis to the addition of a 
piperazine ring in carbon 7 enhancing their activity against gram (-) 
bacteria and some gram (+). The piperazine ring enhanced the 
penetration power across the bacteria cellular wall. They were used 
until the end of 70’s when greater changes in the structural 
composition were made in order to increase the activity and the action 
spectrum.  
 
Figure 1.6. Examples of first, second and third generation FQ respectively.  
 
One of those bigger changes was the addition of a fluorine atom in 







The relation between the biological activity and the chemical 
structure of these molecules motivated the synthesis of compounds 
with new substituents trying to increase the efficiency, power, and 
action spectrum and, in addition, decrease their side effects. In that 
sense, third generation quinolones appeared with longer plasma half 










1.5.3.1. Fluoroquinolones’ mechanism of action 
Quinolones are the only known antibacterial compounds that act 
against bacterial topoisomerases II and IV. These enzymes are 
responsible for adequate coiling in chromosomic regions. Quinolones 
inhibit the activity of DNA-gyrase avoiding DNA reparation and recovery 
of its supercoiled form ending the cellular division.  
The mechanism of action proceeds through the formation of a 
quinolone-enzyme-DNA complex. The binding of the quinolones to the 
enzyme induces a conformational change in the enzyme-DNA 
complex.88 
Several studies have been carried out evidencing the antitumoral 
activity of fluoroquinolones. Depending on the FQ the mechanism of 
action is different.  
- Cell cycle arrest inducers: ciprofloxacin is an example that produce 
phase arrest in S/G2 phase in prostate and bladder cancer cells.89,90 
Another strategy to produce cell cycle arrest is the inhibition of 
involved enzymes like cyclin-dependent kinases Miofloxacin in 
pancreatic cells.90  
- Apoptotic agents: cancer is sometimes a consequence of non-
regulated apoptosis. The lack of apoptosis is translated to tumor 
formation, metastasis and even drug resistance.91 Some examples 






showed that exposure of Ciprofloxacin and Levofloxacin to UVA light 
leads to apoptosis.92 
- Adjuvant chemotherapy enhancers: combinatorial administration of 
anti-cancer drugs is highly effective due to the different mechanisms 
of action of co-administered drugs. An example of combination 
drugs is Enoxacin (FQ) and Doxorubicin.93 
1.5.3.2. Fluoroquinolones’ photogenotoxicity 
In the presence of ultraviolet radiation (UV) fluoroquinolones reveal 
an enhancement of its genotoxicity in eukaryotic systems. Previous 
studies unveil that photoactive FQs experience a photodehalogenation 
by heterolysis of their C8-halogen bond producing reactive 
intermediates which produce biological damage. 94 
1.6. Photosensitized release 
Conventional drug delivery systems have certain drawbacks such as 
the lack of control in the distribution of the therapeutic agent and the 
low concentration at the target site. Associated with these problems 
are the efficiency and toxicity of the drug. All these drawbacks translate 
into side effects in the patient.95 
Nanomedicine has appeared as a promising option to overcome 
such differences. The base behind this option is the use of nanoparticles 






time and decreasing side effects by delivering the drugs in target 
sites.96–98 
The effect known as enhanced permeation and retention (EPR) can 
be achieved by synthesizing nanoparticles with sizes between 30 nm 
and 200 nm which will accumulate preferentially in tissues with 
deficient vasculatures such as the tumor ones.99 It can lead to an 
enhancement of the therapeutic effect.  
Different sources for external trigger can be used as energy ones 
such as magnetic 100 fields, ultrasound 101 or light.102 As mentioned 
before, light has been used in many different ways in medicine from 
photosensitizing to therapeutic use itself like photodynamic therapy 
(PDT). Centering the attention in the photochemical reactions, they 
need high energy emitting from UV/visible wavelength to occur. 
Nevertheless, it has poor penetration tissue depth and causes cell 
damage by reaction with biomolecules. In contrast, NIR light overcomes 
those problems but it usually has low energy to produce photochemical 
reactions. Up-conversion nanoparticles are able to mix the best of both 
radiations. They can absorb NIR light and emit UV/visible light avoiding 
the problems of tissue penetration and cell damage from UV light and 
the low energy of NIR light.103,104 
1.6.1. Loaded drugs 
Conformational changes in the carriers after NIR irradiation leads to 






Two examples of those techniques are the drug loading in mesoporous 
silica by hydrogen bond interactions or prodrug load in mesoporous 
silica. Not only drugs can be loaded, but also other molecules such as 
siRNA or bioimaging dyes. 
1.6.2. Conjugated drugs 
One way to achieve drug delivery from UCNP is the direct 
conjugation of the therapeutic molecule to the nanoparticle surface105. 
Another way is the use of photocleavable prodrugs.106,107 These 
prodrugs are composed by the therapeutical agent and a 
photocleavable protecting group (PPGs). PPGs have been used with 
other purposes apart from drug delivery such as volatiles release 108,109 
or polymerization, among others.110,111 A good PPG may have some 
special characteristics like a high quantum yield to have a clean and 
efficient photoreaction. In addition, if during the photochemical 
reaction side products are generated, they should not react with the 
studied media and they should not absorb in the working wavelength 
in order to avoid competitive absorption.  
The first and more used PPGs are the nitroaryl compounds, but their 
photolysis generates toxic photoproducts with high absorption in the 
working range. For that reason, several PPGs have been developed 
during the last decades. Some examples of PGGs are the metal-






the arylcarbonylmethyl group, among others.112 In this section 
coumarin and nitrobenzyl groups will be described. 
1.6.2.1. Coumarin-4-ylmethyl groups 
First coumarins used as PPGs were 7-methoxycoumarinyl-4-methyl 
and they were the base for new cages. Variations in their maximum 
absorption can be achieved by modifying C6 and C7.112  Regardless, low 
water solubility still remains unresolved in this first generation 
coumarins. The addition of an alkoxy group in C6 contributes to a red 
shifting of the absorption maximum. Second generation 
coumarinylmethyl cages achieves better photochemical and 
spectroscopic properties and, moreover, shifts the absorption maxima 
until 350-400 nm by adding 7-amino substituents.113 In order to solve 
the water solubility problem, which is really important for biological 
applications, different polar groups such as carboxylic acids have been 
added.  
The photorelease mechanism depends on the selected leaving 
group. In the case of alcohols, thiols and phenols, the derivatives render 
resistant to heterolysis. The best strategy is the use of a carbonate 
linkage.  
Amines proceed with a slow rate.114–117 As shown un Figure 1.8, 
decarboxylation of carbamate anion is the rate-limiting point. It will be 
dependent on the released amine and the pH.118,119 This slow release is 







Figure.1.8. Photorelease of thiols, amines, and alcohols 
The most successful leaving groups are carboxylic acids, sulfonates 
and phosphonates. After irradiation, consequent absorption, and 
relaxation to lowest singlet excited state, three different options may 
occur: 
- Radiationless decay 
- Fluorescence 
- Heterolytic bond cleavage 
The intermediate formed at the beginning by tight ion pair is the 
key. Coumarin-methyl cation reacts with solvent or nucleophiles to 
yield a stable product. On the other hand, tight ion pair can escape the 
cage and react with nucleophiles. After the recombination of the ion 
pair, the caged derivative comes back to the ground state via 
nonproductive pathway.120–122  
Even though the heterolytic bond cleavage rate constant for these 
cases is very fast, ion pair recombination is quicker. The addition of 
electron-donor groups in the coumarin derivatives and selection of 







1.6.2.2. Orto-Nitrobenzyl groups 
Despite their disadvantages, o-nitrobenzyl groups have been widely 
used as PPGs. The changes in their substituents are crucial for the 
chromophore absorption spectrum and, in addition, for the stability of 
the photocleavable bond. Minor changes create PPGs able to 
photocleavage at different wavelengths (from 345 to 420 nm).113,123,132–
134,124–131 
The addition of an electron-withdrawing group at para-position is 
an easy way to obtain a red shifted absorption. Moreover, the change 
in meta-position by the addition of an electron-donating group allows 
longer wavelength cleavage. 125–127,131,133 
 







After irradiation, hydrogen abstraction by nitro group occurs.135 
Either from singlet or triplet, the return to the ground state takes place 
via π-electron reorganization forming the aci-nitro intermediate (see 
figure 1.9). This process is faster than the intramolecular back-reaction. 
When o-nitrobenzyl derivatives carries a leaving group at benzylic 
position, the photoliberation reaction takes place via aci-nitro 
intermediates. Decay of these intermediates strongly depends on the 
substituents, the solvent, and the pH. The direct attachment of alcohols 
and amines is possible but the use of carbonic derivatives, which make 
them a better leaving group is more frequent.136,137  
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This doctoral thesis focuses on developing new anticancer 
treatments by using new prodrugs and nanoparticles. The new 
treatments will be created combining drugs used or not for cancer 
treatments with up-conversion nanoparticles and using near infrared 
light.  
Accordingly, this has been approached through the following 
specific objectives, which correspond to the different chapters of this 
Doctoral Thesis: 
1. To synthesize new fluoroquinolones with higher photogenotoxic 
effect and undertake complete photochemical, photophysical 
and phototoxic characterization. 
2. To undertake a complete study of fluoroquinolone-biomolecules 
interaction under light with the new fluoroquinolones. 
3. To develop and study new material based on biocompatible up-
conversion nanoparticles carried with the most phototoxic 
fluoroquinolone. 
4. To analyze the photophysical and photochemical properties of 
new prodrugs using a 7-aminomethyl coumarin derivative as the 
photolabile molecule.   
5. To create a new material based on biocompatible up-conversion 
nanoparticles carried with prodrugs made with a 7-aminomethyl 














Chapter 3: Chemical tuning for 








Quinolones are “building blocks” with flexible synthetic routes that 
can be adapted to prepare large libraries of bioactive compounds. Since 
1962, 4-quinolone-3-carboxylic acid derivatives are widely used as 
antibacterial agents and for tuberculosis treatment.1,2 Moreover, 
during the last few years, structural modifications on quinolones have 
shown that this type of compounds can also display antitumor and/or 
antiviral activities.3–9 Thereby, both, high activity of these drugs against 
eukaryotic topoisomerase and their relevant toxicity to cultured 
mammalian cells and in vivo tumor cells,10 clearly show their potential 
as new anticancer agents. A family of modified quinolones with 
antitumor activity that reduce all-cause mortality among cancer 
patients are the fluoroquinolones (FQ). 11 
 
Chart 3.1.Chemical structure of dihalogenated FQs 
Interestingly, a recent study reported an enhancement of the FQ 
genotoxicity in an eukaryotic system by UV irradiation,12 which also 
confers to these drugs a potential property as photochemotherapeutic 
agents. In this context, phototoxicity and photogenotoxicity have been 






(FLX), BAY y3118 (BAY) as well as lomefloxacin (LFX, compound used as 
standard for photomutagenic studies, see structures in Chart 3.1).13–21 
Consequently, a large number of studies concerning the photophysical 
and photochemical properties of 6,8-dihalogenated FQ in the presence 
and/or absence of biomolecules have been carried out. An unusual 
photodehalogenation of these FQ by heterolysis of their C8–halogen 
bonds is the key point in the photoinduced biological damages. The FQ 
photosensitivity reactions have been associated with the generation of 
reactive intermediates in their photodehalogenation processes.22–28 In 
fact, two pathways have been proposed to explain the photoinduced 
adverse effects observed for this type of FQ: I) an aryl radical (FQ(-F)·) 
is generated from an intermolecular electron transfer between FQ 
singlet excited state and a complexed electron donor biomolecule, and 
II) an aryl cation with alkylating properties is formed from the 
heterolytic dehalogenation of its FQ triplet excited state (3FQ) (see 
Scheme 3.1).26–28 Interestingly, it has been observed in FQ 
photodegradation studies that peripheral substituents of FQ skeleton 
such as  the piperazinyl ring and or the N(1) alkyl substituents react with 
the aryl cation (FQ(-F)+ to produce photoproducts, hindering 
intermolecular photoreactions with biomolecules or molecular oxygen 
(see pathway II in Scheme 3.1).27,28 Photoallergy is mainly produced 
from pathway I,27 however, the contribution of routes I and II is still 







Scheme 3.1. Proposed mechanisms for the photodehalogenation process of 
6,8-difluoroquinolones (FQ) in presence of biomolecules (BIO). 
With this background, the aim of the present study is to enhance 
the phototoxic potential of FQ in order to obtain drugs with more 
photochemotherapeutic properties. For this purpose, it was thought to 
decrease the FQ peripheral size for improving the efficiency of the 
intermolecular photoreactions between FQ and biomolecules or 
molecular oxygen via pathway II. Thus, a new tailored 6,8-
dihalogenated FQ (1-methyl-6,8-difluoro-4-oxo-7-aminodimethyl-1,4-
dihidroquinoline-3-carboxylic acid (1), see Chart 3.1 was synthesized.  
In order to probe this hypothesis, photophysical and photochemical 
studies (fluorescence emissions, time resolved and steady state 
photolysis) will be combined together with in vitro cell cultured 
experiments (3T3 NRU phototoxicity assay) using FQ derivatives with 
different peripheral substituents (see chemical structures in Chart 3.1). 







acid (2).29 Moreover, the role of the FQ photodehalogenation pathways 
in the phototoxic properties associated with FQ will be also evaluated. 
3.2.  Results and discussion 
3.2.1. Absorption spectra of fluoroquinolones 1 and 2 
The absorption spectra of 1 and 2 showed almost identical UV-Vis 
spectral features (see Figure 3.1). Nevertheless, in the case of LFX, 
although its absorption maxima were also similar to those of 1 and 2, 
some changes can be observed, indicating that some photophysical 
properties of the quinolone chromophore change by the presence of a 
piperazinyl ring. 
 
Figure 3.1. Absorption (left) and fluorescence (right) of compound 1, 2 and LFX 
(4 x 10-5 M) in 2 mM PB aqueous medium. Inset: Phosphorescence of 1 in 
aqueous medium at 77 K. The emission measurements were performed at the 






3.2.2. Emission measurements of fluoroquinolones 1 and 2  
Fluorescence spectrum of LFX under neutral conditions (1 mM PB 
aqueous medium, pH ca. 7.4) showed an emission band with a 
maximum at 415 nm as described in the literature.22 However, the 
fluorescence spectra of 1 and 2 display bands at λmax ca. 445 and 455 
nm respectively, exhibiting a redshift effect. In this context, 
fluorescence quantum yields (ϕFl) of 1 and 2 resulted to be markedly 
lower than that described for LFX (ϕFl ca. 0.08) but their emission 
lifetimes were similar (Table 3.1).   
Table 3.1. Emission and photochemical properties of LFX, 1 and 2 in aqueous 
media. 
 aFl bPh cϕD 
FQ λmax nm ϕFl τFl  ns λmax nm H2O 
H2O/EtOH 
(1/1) 
LFX 415 0.080 1.3 480 0.55  
1 445 0.008 1.2 480 0.40 0.62 
2 455 0.008 1.3 480 0.75 0.76 
aIn aqueous medium. bIn frozen buffered aqueous media at 77 K.                           
cPhotodegradation quantum yields were determined taking as standard LFX in 
water (ϕD = 0.55) 25. 
When phosphorescence measurements of 1, 2 and LFX were 
performed in frozen buffered aqueous media at 77 K, their emission 
spectra resulted to be almost identical (see inset Figure 3.1 for 
phosphorescence of 1). Thus, a triplet energy ca. 273 kJ/mol was 






The decay traces of singlet-oxygen (1O2) phosphorescence at 1270 
nm generated by pulsed-laser irradiation at 355 nm of aerated 
deuterated aqueous neutral solutions (1 mM PB aqueous medium, pH 
ca. 7.4) of LFX, 1, 2 and perinaphthenone as reference were recorded 
to determine 1O2 quantum yield (ϕΔ)of these FQs. The values obtained 
revealed ϕΔ for LFX, 1 and 2 lower than 0.005. The result obtained for 
LFX is not completely in agreement with the value described in the 
literature (ϕΔ ca. 0.07 in buffered deuterated water).30 However, as 
photodegradation quantum yield (ϕD) of LFX  is very high (ϕD = 0.55),25 
the value described could have increased due to 1O2 generation from 
photoproducts generated during the measurements. In fact, we 
observed that the use of several fresh samples during the acquisition of 
the value of each dihalogenated fluoroquinolone was needed. 
3.2.3. Laser flash photolysis studies (LFP) of fluoroquinolones 1 and 2  
Laser flash photolysis of 1 and 2 were carried out in buffered water 
(1 mM PB) under different atmospheres using LFX as reference 
compound. Thus, LFX under N2O atmosphere at pH = 7.4 showed the 
presence of an aryl cation with λmax 480 nm and a lifetime (τ) of 250 ns, 
data very similar to those described in the literature.22–24 When the 
experiments were performed using 1, an intermediate absorbing also 
at λmax 480 nm was also detected (see Figure 3.2). However, this 
intermediate showed longer lifetime (τ ca. 3.1 µs) than the observed 
for LFX. A reactivity study using molecular oxygen was performed in 
order to determine the nature of the intermediate arising from 






x 10-3 M did not show any effect on the intermediate lifetime discards 
a triplet excited state nature. Hence, to achieve an unambiguous 
assignment of this transient species, compound 1 was submitted to LFP 
in the presence of a nucleophilic anion such as Br-. The efficient 
quenching by Br- showed a rate quenching constant of 1.5 x 1010 M-1 s-
1, a value very close to those reported for aryl cations generated from 
LFX and other dihalogenated FQ such as BAY y3118 or fleroxacin.23,31 

























Figure 3.2. Transient absorption spectra of 1 (10-4 M) in aqueous 1 mM PB in 
N2O atmosphere at different times after the 355 nm laser excitation. Inset: 
Decay traces at 470 nm of 1 under the same conditions in the presence of 
different concentrations of Br- anion.   
Interestingly, LFP assays using 2 in aqueous solutions showed two 
consecutive transient species (see Figure 3.3). The first one displayed 
an absorption spectrum with a λmax 470 nm with a τ < 300 ns and the 
second one at λmax 460 nm and a τ 980 ns. It was observed that the two 
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bands were not appreciably quenched or modified by the presence of 
O2 atmosphere, whereas they were affected by the presence of the Br- 
anion. Apparently, the first intermediate seems to be reactive to the 
anion while the second one decreases its absorbance (see inset of 
Figure 3.3). Thereby, the structure of the first transient species would 
be attributed to an aryl cation (FQ(-F)+) similar to the describe for most 
of the dihalogenated FQ including 1. The assignment of the second one 
could be a diradical cation (FQ(-F)¨+) arising from the first intermediate 
(see Scheme 3.1) as it has previously been proposed in the photolysis 
of N-acetylated LFX.22 
In this context, highlight the absence of any detectable triplet 
excited state corresponding to the FQs, which is in agreement with the 




































Figure 3.3. Transient absorption spectra of 2 (10-4 M) in aqueous 1 mM PB in 
N2O atmosphere at different times after the 355 nm laser excitation. Inset: 
Decay traces at 450 nm of 1 under aerobic condition in the presence and/or 
absence of Br- anion. 
When the LFP of 1, 2 and LFX were carried out under N2 atmosphere, 
besides detecting the same transient species with similar lifetimes than 
in the experiments performed in N2O, an intermediate absorbing at λmax 
ca. 720 nm was observed. The spectrum absorption shape and the high 
quenching rate constant by oxygen and N2O (> 109 M-1 s-1) supports its 
assignment as the solvated electron. In fact, this intermediate has been 
observed in neutral aqueous medium by excitation at 355 nm through 
a two-photon process under moderate laser energy conditions in all FQ 
studied under similar conditions.23,32–34 In this context, in agreement 
with the literature,22–28 the solvated electrons detected under N2 or the 
hydroxyl radicals generated from the reaction of solvated electrons 
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with N2O do not seem to modify the lifetime of the detected 
intermediates. 
 
3.2.4. Photodegradation studies 
Irradiations of 1 and 2 in deaerated aqueous solutions at pH ca. 7.4 
using LFX as reference compound were performed in a multilamp 
photoreactor using UVA light at λmax = 350 nm. Kinetics studies showed 
different photodegradation quantum yields (ϕD) for 1, 2 and LFX (Table 
3.1). Analysis of the photoreactions revealed a photodegradation 
quantum yield (ϕD) of 0.4 for 1 but only a small number of 
photoproducts were detected being the major photoproduct with 1P 
with a formation quantum yield (ϕPF) lower than 0.02 (see structure in 
Scheme 3.2). Thereby, a photopolymerization process justifies the high 
ϕD of 1. Interestingly, photolysis of 2 showed the highest ϕD giving rise 
mainly to 2P1 (ϕPF 0.75) and small amounts of 2P2 (ϕPF of 0.05) (see 
Scheme 3.2). In this context, significant changes were observed when 
the photodegradation of 1 was carried out using a hydrogen donor 
media such as a mixture of ethanol/water (2 mM PB) 1/1. In fact, ϕD of 
1 increased to 0.62 and the ϕPF of its photoproduct 1P grew up to 0.20. 
By contrast, ϕD of 2 did not appreciably change in the aqueous alcoholic 
medium (ϕD = 0.76) although ϕPF of its photoproducts was modified (ϕPF 
of 0.70 and 0.14 for 2P1 and 2P2 respectively). The structures of 1P, 
2P1 and 2P2 were unambiguously assigned using the spectroscopic 








Scheme 3.2. Photodegradation pathways of 1 and 2 in aqueous media. 
3.2.5. Phototoxic properties 
Cell viability upon incubation with LFX, 1 and 2 in combination with 
UVA light was assessed by the in vitro 3T3 NRU phototoxicity test. Thus, 
cytotoxicity profiles of BALB/c 3T3 fibroblasts treated with LFX, 1 and 2 
were measured in the presence and absence of UVA light, using neutral 
red as vital dye, and half maximal inhibitory concentration (IC50) were 
determined from dose-response curves (see Figure 3.4). 
This test is based on the calculation of the Photo-Irritation-Factor 
(PIF) that corresponds to the ratio of the IC50 for each compound with 








Figure 3.4. Dose-Response curves for cell viability of 3T3 cells treated with SDS, 
LFX, 1 and 2 by using neutral red vital stain (NRU) assay in the presence (□) or 
absence (■) of UV Light. Data represent Mean±SD from four independent 
experiments. SDS and LFX were used as negative and positive control of 
phototoxicity, respectively. 
 
Table 3.2. In vitro 3T3 NRU phototoxicity assay of LFX, 1 and 2. 





LFX > 500 50±8 > 10 
1 > 500 16±9 > 30 
2 > 500 65±26 > 8 
SDS 220±21 244±25 1 
Data represent mean ±SD from four independent experiments. LFX and SDS 






aAccording to the OECD (2004)35, PIF<2 means “No Phototoxicity”, 2<PIF<5 
means “Probably Photototoxicity” and PIF>5 means “Phototoxicity”. 











Figure 3.5. Data represent the Photo-Irritation-Factor (PIF) determined using 
the equation PIF=IC50 DARK/IC50 UVA LIGHT. The IC50 were determined from 
the 3T3 NRU assay. 3T3 cells were treated with serial dilutions of LFX, 1 and 2 
ranging from 0.5μM to 500μM for 1h, followed by irradiation (or not) with a 
dose of 5J/cm2 UVA light. LFX and SDS were used as positive and negative 
control of phototoxicity, respectively.35,36 After 24 h cell viability was 
determined by neutral red uptake and IC50 values were calculated by non-lineal 
regression with GraphPad Prism 5.0. 
As shown in Table 3.2 and Figure 3.5, LFX was clearly phototoxic as 
anticipated (PIF ca. 10). For 2 a toxicity with a PIF of ca. 8 was obtained. 
Interestingly, the effect observed for 1 resulted to be higher than LFX 
and 2 (a 3-fold increase of the IC50 was determined, PIF ca. 30). 
Noteworthy, only 1 displays a N(1) methyl substituent. Hence, the 
different behavior shown in phototoxic assays may be modulated by 
the N-alkyl chain of the fluoroquinolones. However, as FQ location in 
cells could modify the biomolecules photodegradation and, 






2 in FSK cells was performed by confocal microscopy. Interestingly, as 
shown in Figure 3.5, similar cytoplasmic distribution is observed for all 
compounds (blue emission), indicating that the higher photo-toxicity of 
1 relative to LFX and 2 can not be attributed to damage of different 
cellular targets. 
 
Figure 3.6. Confocal microscopy images of intracellular localization of LFX (A), 
1 (B) and 2 (C) in FSK cells (blue fluorescence). Representative images were 
selected from three different regions on the slide. 
 
Scheme 3.3. Photodegradation pathways of 1 and 2 in presence of hydrogen 






The photophysical, photochemical and photobiological properties 
found for 1 and 2 together with those described in the literature for 
other dihalogenated FQ22–28,35 were analyzed to rationalize the possible 
mechanisms involving the photosensitized cell damage produced by 
the dihalogenated FQ 1 and 2.  
Initially, as the UV-induced biomolecules damage in the presence of 
FQs can involve a triplet-triplet energy transfer reaction, 
photosensitized generation of 1O2 and radicals generation from FQ 
photodehalogenation,13,37 all of them would be evaluated to determine 
the mechanisms responsible for the phototoxic properties associated 
with the dihalogenated quinolones. However, the lack of detection of 
any triplet excited state for LFX, 1 and 2 in the laser flash photolysis 
experiments and the almost unappreciable singlet oxygen generation 
from the three dihalogenated quinolones clearly evidence that the 
photodehalogenation of these FQs is their major process to produce 
the biological damage. The apparent inconsistency between the lack of 
detection of LFX triplet excited state and the described LFX-
photosensitized formation of cyclobutane dimers in cellular DNA,37 
which must occur via triplet-triplet energy transfer mechanism,38 could 
be understood through the participation of LFX photoproducts  
because the photodehalogenation is highly efficient process for LFX. In 
fact, this also explains why a 1O2 generation quantum yield of 0.07 had 
been described for LFX.30 Thereby, the main pathways involving 
photodehalogenation of LFX, 1 and 2 are shown in Scheme 3.3. As 






quinolones,26–28  the most relevant photosensitization processes 
associated with dihalogenated FQ including compound 1 and 2 can be 
understood from photodehalogenation pathways I and II. However, the 
results obtained in this study have evidenced that the reactions arising 
from II must be the key processes in the FQ photosensitized cell 
damage. In this context, photophysical and photochemical properties 
of 1, 2 and LFX were compared to determine the effects of peripheral 
substituents such as the N(1)alkyl or the piperazinyl ring. Thus, although 
most of the photophysical properties of 2 are quite different to that of 
LFX (see Figure 3.1 and Table 3.1), photodegradation of aqueous 
solutions of 2 mainly produces photoproduct 2P1 (see via IIa in Scheme 
3.3), a tricyclic compound similar to the main photoproduct of LFX.26–28 
An intramolecular hydrogen abstraction reaction between the aryl 
carbene of 2 and its N(1)ethyl group initiates a cyclization route  to form  
2P1 (intermediates involving this process are shown in Scheme 3.2). By 
contrast, photoproduct analysis of the irradiation of 1 revealed the 
inability of the aryl carbene FQ(-F-): of 1 to react with its N(1)-methyl 
substituent. These results can be correlated with the results of laser 
flash photolysis experiments, where the detected aryl cations arising 
from 1 and 2 showed important differences in the generation and 
lifetime of their aryl cations (see Figure 3.1 and Figure 3.2). Hence, a 
fast intramolecular rate constant between a carbene FQ(-F-): and its 
N(1)-ethyl substituent can justify the observed decrease in the 
generation and lifetime of the aryl cations arising from 2 and also from 
LFX. Thereby, the longer lifetime of the aryl cation of 1 produces an 






with its released fluorine anion (via IIc, which clarifies the lower 
photodegradation quantum yield of 1 than that of 2 or LFX under the 
same conditions (Table 3.1)) or with 1 ground states (via IIb, which can 
be the first step of a polymerization process). In this context, pathway 
IIb can also explain the degradation changes observed in the photolysis 
of 1 and 2 when they were performed using a hydrogen donor solvent 
such as ethanol (see results in Table 3.1). Thus, the presence of high 
amounts of hydrogen donor molecules in the photoreaction media 
produces a reaction rate increase of the aryl carbene FQ(-F-):  
generated from 1 or 2 with ethanol, which improves the formation of 
photoproduct 1P or 2P2, respectively.  By contrast, the efficiency of the 
other hydrogen abstraction processes is reduced. Hence, the presence 
of ethanol in the photodegradation of 1 also produces a decrease of the 
intermolecular reactions of the aryl carbene FQ(-F-):  with its ground 
state (see via IIb in Scheme 3.3) and with fluoride anion via IIc (Scheme 
3.3). Consequently, a low photopolymerization of 1 and a growth of its 
photodegradation quantum yield (see Table 3.1), respectively, is 
observed. In the case of 2, as its intermolecular reactions of via IIb 
compete mainly with the intramolecular pathway IIa (see Scheme 3.3), 
the presence of ethanol reduces the amounts of 2P1.  
These findings resulted to be relevant to understand the cellular 
damage photoinduced by FQ when in vitro 3T3 NRU assays were 
performed. Thus, a clear correlation between the photodehalogenation 
process of route II and phototoxic effects in cultured cells was found 






in the presence of fibroblast cells seems to indicate that the main 
pathway involved in its phototoxicity is pathway II because only this 
route can be influenced by the reactivity of the N(1)-alkyl chain of FQ 
(Scheme 3.2 and Scheme 3.3). Intermolecular reactions between 
biomolecules and the intermediates arising from FQ dehalogenation 
are the main processes involved in the phototoxicity of 1 (see pathways 
IIb and IId in Scheme 3.3), however for 2 and LFX, annihilation of their 
aryl carbenes by coupling of them with their N(1)-ethyl groups is an 
efficient process competing with pathways IIb and IId. The 
interpretation of the findings could be incorrect if the cellular location 
of 1, 2 and LFX was different because this fact could modulate the 
biomolecules photodegradation and consequently the phototoxic 
effects. Interestingly, as shown in Figure 3.6, similar cytoplasmic 
distribution is observed for all compounds (blue emission), indicating 
that the higher phototoxicity of 1 relative to LFX and 2 cannot be 
attributed to damage of different cellular targets. 
3.3. Conclusion 
A new FQ (1) with a N(1)-methyl group has been synthesized, the 
reduction in the length of the N(1)-alkyl chain of FQ reveals significant 
changes in the FQ photodehalogenation processes. Thus, an increase in 
the generation efficiency and lifetime of a reactive intermediate is 
observed and the photoproducts formation is also modified. Besides, 
the results of in vitro 3T3 NRU assays revealed a higher phototoxicity 
for 1 than those with longer a N(1)-alkyl chain. All the results can be 






intermediate with its N(1)-methyl substituent. Moreover, the higher 
phototoxicity for 1 also confirms that the photodehalogenation arising 
from the free FQ (in bulk water) is the main pathway involved in the 
phototoxic processes. This study provides a way for tuning the 
phototoxicity of FQ, which could be used to enhance this adverse effect 
as a photochemotherapeutic property to improve their antitumor 
activity.  
3.4. Experimental section 
3.4.1. Materials 
Ethyl 6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate and 
lomefloxacin (LFX) were from Sigma Chemical Company (St Louis, MO). 
Sodium phosphate buffer was prepared from reagent-grade products 
using milli-Q water; the pH of the solutions was measured through a 
glass electrode and adjusted with NaOH to pH 7.4. Other chemicals 
were of reagent grade and used as received. 
3.4.2. Synthesis of fluoroquinolones 
1-Methyl-7-dimethy1amino-6,8-difluoro-1,4-dihydro-3-
quinolinecarboxylic acid (1). To 5.89 g (21.7 mmol) of ethyl 6,7,8-
trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate were added 7.5 g 
(2.5 equiv.) of K2CO3 and 300 mL of dry DMF. After the mixture was 
stirred for 30 min at 50 °C, 20 ml (ca. 11.0 equiv.) of iodomethane were 
added. The temperature was raised to 80 °C, and the mixture stirred 
vigorously for 48 h. It was concentrated to dryness and the residue was 






was dried and concentrated to yield a dark oil.  To 2.2 g (7.4 mmol) of 
this material were added AcOH (40 mL) and HCl (20 ml, 3N) and the 
mixture was heated for 5 h. Dilution with water and filtration gave 1.3 
g (64 %) of l-methyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinoline-
carboxylic acid.39 
To 1.00 g (3.5 mmol) of l-methyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-
3-quinoline-carboxylic acid in 25 mL of CH3CN was added a solution of 
0.55 g (1.0 equiv.) of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 1 
ml (1.1 equiv.) of dimethylamine in 5 mL of CH3CN. The mixture was 
refluxed for 4 h and was stirred at room temperature overnight. Then, 
the solid was filtered and washed with 20 mL of CH3CN, 10 mL of 80% 
aqueous CH3CN, 20 mL of ethanol, and 20 mL of ether to give 1.01 g 
(75%) of 1 (amorphous solid).  
1H NMR [CDCl3, 300 MHz] δ 2.95 (s, 6H) 4.09 (d, 3H, J=14.7 Hz), 7.8 
(d, 1H, J=14.7 Hz), 8.60 (s, 1H). 13C NMR [CDCl3, 75 MHz] δ 42.03, 45.68, 
106.27, 107.64, 118.0, 127.06, 134.67, 144.6 (CF, J = 270.25 Hz), 
149.75, 153.9 (CF, J = 270.25 Hz), 165.21, 175.23. Exact Mass: m/z 
found 283.0894, calculated for C13H13F2N2O3 (MH+) 283.0894. The UV-
Vis spectra of 1 in 2 mM PB aqueous medium shows λmax at 280 and 320 
nm (1H and 13C NMR spectra are shown in Section 3.5). 
1-Ethyl-7-dimethy1amino-6,8-difluoro-1,4-dihydro-3-







quinolinecarboxylic acid (1) were employed to obtain 2 (1H and 13C NMR 
spectra are shown in Section 3.5). 
3.4.3. Emission measurements 
The FQ samples were prepared at 1mM PB concentrations starting 
from a stock solution of 200 mM PB adjusted at pH 7.4. The pH changes 
were induced adding different amounts of HCl or NaOH (12 M) to the 
neutral samples. These measurements were performed with a Crison 
pH-meter.  
Fluorescence emission spectra were recorded on a Photon 
Technology International (PTI) LPS-220B fluorimeter. The fluorescence 
quantum yields were determined by comparing the areas under the 
emission curves with that obtained with quinine bisulfate in 1 N H2SO4, 
a widely used fluorescence standard (φFl = 0.546). Isoabsorptive 
samples at 310 nm (A310nm = 0.3) were used. All measurements were 
recorded at room temperature using 1 cm pathway quartz cells with 4 
mL capacity.  
Phosphorescence spectra were obtained from a Photon Technology 
International (PTI, TimeMaster TM-2/2003) spectrofluorometer 
equipped with a pulsed Xe lamp. The apparatus was operated in time-
resolved mode, with a delay time of 0.5 ms. For phosphorecence 
measurements samples similar to those described were used to obtain 
the fluorescence data. 
Singlet-oxygen measurements were performed by registering 






a Peltier-cooled (- 62.8 ºC) Hamamatsu NIR detector operating at 650 
V, coupled to a computer-controlled grating monochromator. A pulsed 
Nd:YAG L52137 V LOTIS TII was used at the excitation wavelength of 
355 nm. The single pulses were of ca. 10 ns duration, and the energy 
was lower than 5 mJ per pulse. The system consisted of the pulsed laser, 
a 77250 Oriel mono-chromator coupled to the Hamamatsu NIR 
detector and the oscilloscope connected to the computer. The output 
signal was transferred from the oscilloscope to a personal computer. 
All measurements were made at room temperature, under air 
atmosphere, and using deuterated water at pH ca. 7.4 (1mM PB) as 
solvent in 10 × 10 mm2 quartz cells with a capacity of 4 mL. The 
absorbance of the samples was 0.30 at the laser excitation wavelength. 
Perinaphthenone in water (singlet oxygen quantum yield (ϕΔ ca. 
0.98)40 was used as standard to estimate ϕΔ of each compound by 
comparing the phosphorescence intensities at 1270 nm. The signal was 
obtained from the average of 50 laser shots. In this context, fresh 
samples were used every five laser shots to obtain the luminescence of 
singlet oxygen at 1270 nm. 
3.4.4. LFP measurements 
A pulsed Nd:YAG SL404G-10 Spectron Laser Systems was used at the 
excitation wavelength of 355 nm. The single pulses were ~10 ns 
duration and the energy was lower than 10 mJ/pulse. The detecting 
light source was a pulsed Lo255 Oriel xenon lamp. The LFP system 
consisted of the pulsed laser, the Xe lamp, a 77200 Oriel 






of a 77348 side-on PMT tube, 70680 PMT housing and a 70705 PMT 
power supply. The oscilloscope was a TDS-640A Tektronix. The output 
signal from the oscilloscope was transferred to a personal computer. 
Unless otherwise stated, all samples used were in aqueous solutions 
at pH 7.4, and the absorbance was set at 0.3 at 355 nm. Each sample 
was deaerated by bubbling N2O in order to remove the solvated 
electron. Spectra and decays were registered from solutions prepared 
at different pHs by addition of NaOH or HCl to the neutral buffered 
solution.  
Determination of the quenching rate constants of the intermediates 
arising from 1 and 2 by sodium bromide (NaBr) were carried out using 
increasing amounts of the quenchers (from 1 to 400 mM) ensuring that 
no changes in the pH were induced. Under these conditions more than 
99 % of the light was absorbed by the fluoroquinolone. 
To determine every FQ quenching rate constant (kq) the Stern-






+ 𝑘𝑞[𝑄]    Eq. 3.1 
where τ0 is the lifetime of transient species without quencher (Q).  
 
3.4.5. Irradiation procedures and equipment 
Irradiations were performed in a multilamp photoreactor equipped 






distribution), with a maximum at 350 nm. The photoreactions were 
performed under anaerobic conditions using FQs (5 x 10-5 M) in 1 mM 
PB aqueous medium and in 2 mM PB/ethanol (50/50). The kinetic 
studies to determine photodegradation quantum yields of 1, 2 and LFX 
and the generation of their photoproducts were performed taking 
aliquots after 20, 40, 60, 80, 100 and 120 seconds of irradiation. 
Afterwards, these samples were monitored by HPLC on an analytical 
C18 column (25 x 0.4 cm, mean particle size 5 µm) with flow rate of 0.7 
mL/min and a mixture of acetonitrile/water/trifluoroacetic acid 
50/49.9/0.1 was used as eluent.  
For in vitro phototoxicity assays, the used light source was a 
photoreactor model LZC-Y equipped with 14 lamps for top and side 
irradiation (lamps emitting in the 310-390 nm range with a maximum 
at 350 nm and Gaussian distribution. The irradiation was performed 
through the lid of a 96 well-plate and in order to avoid overheating, the 
plates were placed on ice during the irradiation step. 
The corresponding photoproducts were initially identified by UPLC-
MS/MS. Briefly, the chromatography was performed on an ACQUITY 
UPLC system (Waters Corp.) with a conditioned autosampler at 4 °C. 
The separation was carried out on an ACQUITY UPLC BEH C18 column 
(50 mm × 2.1 mm i.d., 1.7 μm). The column temperature was 
maintained at 40 °C. The analysis was achieved with gradient elution 
using acetonitrile and water (containing 0.01% formic acid) as the 
mobile phase. The Waters ACQUITY™ XevoQToF Spectrometer (Waters 






(ESI) interface. The ESI source was operated in positive ionization mode 
with the capillary voltage at 3.0 kV. The temperature of the source and 
desolvation was set at 100 °C and 400 °C, respectively. The cone and 
desolvation gas flows were 100 L h−1 and 800 L h−1, respectively. All data 
collected in Centroid mode were acquired using Masslynx™ software 
(Waters Corp.). Leucine-enkephalin was used as the lock mass 
generating an [M+H]+ ion (m/z 556.2771) at a concentration of 500 
pg/mL and flow rate of 50 μL/min to ensure accuracy during the MS 
analysis. 
The photodegradation quantum yields (ϕD) were obtained by 
comparison with the value reported for LFX (ca. 0.55), which was used 
as actinometer. 
3.4.6. General procedure to identify photoproducts of 1 and 2 
Preparative deaerated irradiations of 1 and 2 (2 x 10 -3 M) in 2 mM 
PB/ ethanol (50/50) using the procedure described above were 
performed to isolate their major photoproducts.  Thereby, a solution of 
1 (0.283 g in 500 mL of 2 mM PB/ethanol (1/1)) was irradiated for 3 h. 
Subsequently, the photomixture was acidified with HCl (1N) to pH ca. 3 
and extracted with CH2Cl2 (3 x 25mL). The organic mixture was dried 
with MgSO4 and concentrated under reduced pressure. Analysis of this 
photomixture using UPLC-MS/MS revealed the formation of 
photoproduct 1P which shows an exact mass (m/z) found 265.0992, 
calculated for C13H14FN2O3 (MH+) 265.0988.  However, this compound 






(trimethylsilyl)diazomethane, where isolation and characterization 
were done for its methyl ester 1P´ (methyl 1-methyl-7-dimethy1amino-
6-fluoro-1,4-dihydro-3-quinolinecarboxylate). Thus, the photoproduct 
mixture was treated with 300µL of (trimethylsilyl)diazomethane 
(TMSCHN2 2.0 M solution in diethyl ether) in dichloromethane (10 mL) 
for this aim. The reaction mixture was stirred under N2 at 40 C̊ for 2h 
and at room temperature overnight. The reaction mixture was 
neutralized by adding water (10 mL) and extracted with CH2Cl2 (3 x 
25mL). The organic mixture was dried over MgSO4 and concentrated 
under vacuum. Then, this photomixture was submitted to silica gel 
column chromatography, using 55/30/10/5 of 
dichloromethane/cyclohexane/acetone/ethanol as mobile phase to 
isolate 25 mg (9 %) of 1P´ (colorless gum). 
Methyl 1-methyl-7-dimethy1amino-6-Fluoro-1,4-dihydro-3-
quinolinecarboxylate (1P´) 1H NMR [CDCl3, 300 MHz,] δ 2.95 (s, 6H) 3.75 
(s, 3H), 3.87 (s, 3H), 6.40 (d, 1H, J = 6.9 Hz), 7.92 (d, 1H, J=14.7 Hz), 8.30 
(s, 1H). 13C NMR [CDCl3, 75 MHz] δ 40.41, 43.29, 51.99, 101.48, 109.74, 
113.58, 121.27, 137.48, 144.64, 149.20, 151.95 (CF, J = 270.35 Hz), 
166.65, 173.12 (1H and 13C NMR spectra are shown in section 3.5). Exact 
Mass: m/z found 279.1150, calculated for C14H16FN2O3 (MH+) 279.1145. 
The UV-Vis spectrum of 1P´in 2 mM PB aqueous medium shows λmax at 
280 and 320 nm. 
Photoproducts 2P1 and 2P2 were directly obtained from a 
preparative irradiation similar to that described for 1 above but using 2 






of sample irradiation, the photomixture was acidified with HCl (1N) to 
pH ca. 3 and extracted with CH2Cl2 (3 x 25mL). The organic mixture was 
dried over MgSO4 and concentrated under vacuum. Afterwards, the 
photomixture was submitted to silica gel column chromatography, 
using 55/30/10/5 of dichloromethane/cyclohexane/acetone/ethanol 
as mobile phase to isolate two amorphous solids, 2P1 64 mg (23 %) and 
2P2 12 mg (5%).  
1,8-(1,2-ethyl)-7-dimethy1amino-6-fluoro-1,4-dihydro-3-
quinolinecarboxylic acid (2P1) 1H NMR [D2O, 300 MHz] δ 2.80 (s, 6H) 
3.55 (t, 2H, J=7 Hz), 4.57 (t, 2H, J=7 Hz), 7.30 (d, 1H, J=15 Hz), 8.25 (s, 
1H). 13C NMR [D2O, 75 MHz] δ 28.19, 42.79, 52.29, 107.39, 107.73, 
118.53, 119.06, 125.10, 141.03, 141.51, 156.30 (CF, J= 272.15 Hz), 
173.14, 174.75 (1H and 13C NMR spectra are shown in Section 3.5). Exact 
Mass: m/z found 277.0988, calculated for C14H14FN2O3 (MH+) 277.0981. 
The UV-Vis spectrum of 2P1 in 2 mM PB aqueous medium shows λmax 
at 280 and 320 nm. 
1-ethyl-7-dimethy1amino-6-Fluoro-1,4-dihydro-3-
quinolinecarboxylic acid (2P2) 1H NMR [CDCl3, 300 MHz] δ 1.45 ((t, 3H, 
J=6.8 Hz), 3.05 (s, 6H) 3.75 (s, 3H), 4.22 (c, 2H, J=6.8 Hz), 6.45 (d, 1H, 
J=6.9 Hz),  7.84 (d, 1H, J=15.2 Hz), 8.50 (s, 1H). 13C NMR [CDCl3, 75 MHz] 
δ 14.26, 42.21, 49.20, 100.80, 107.83, 112.65, 118.08, 137.42, 145.72, 
146.88, 151.65 (CF, J= 270.35 Hz), 167.41, 176.64 (1H and 13C NMR 
spectra are shown in section 3.5). Exact Mass: m/z found 279.1134, 
calculated for C14H16FN2O3 (MH+) 279.1145. The UV-Vis spectrum of 






3.4.7. In Vitro 3T3 neutral red uptake (NRU) phototoxicity test 
BALB/c 3T3 fibroblasts cell line was grown in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with 4 mM glutamine, 1% 
penicillin/streptomycin 10% and Fetal Bovine Serum (FBS) and routinely 
maintained in exponential growth in 75 cm2 plastic flasks in a 
humidified incubator at 37 C under 5% carbon dioxide atmosphere. The 
3T3 Neutral Red Uptake Phototoxicity Test was performed as described 
by the OECD guideline 432 (OECD, 2004) with minor modifications.35,40 
Briefly, two 96-wells plates (2.5 × 104 cells/well) were seeded for each 
compound. Cells were treated with compounds LFX, 1, 2 and SDS at 
several concentrations ranging from 0.5 μM to 500 μM and incubated 
for 1 h. Afterwards, one plate was irradiated on ice for 11 min to 
achieve a dose of UVA equivalent to 5 J/cm2 (UVA LIGHT), whereas the 
other plate was kept in a dark box (DARK). The viability of UVA-treated 
control cells in the absence of test compounds was > 90% of those kept 
in the dark indicating the suitability of the UV dose. After irradiation, 
the compound solutions were replaced with DMEM medium, and 
plates were incubated overnight. Subsequently, neutral red solution 
(50 μg/mL) was added into each well and incubated for 2 h. Cells were 
washed with PBS and neutral red was extracted in 100 μL with the 
desorbs solution (water 49% (v/v), ethanol 50% (v/v) and acetic acid 1% 
(v/v). Then, the absorbance was measured at 550 nm on a Multiskan Ex 
microplate reader. For each compound dose-response curves were 
established in order to determine the concentration of the compound 






and light. In the end, Photo-Irritation-Factor (PIF) was determined using 
the following equation:  
𝑃𝐼𝐹 =  
𝐼𝐶50 𝐷𝐴𝑅𝐾
𝐼𝐶50 𝑈𝑉𝐴 𝐿𝐼𝐺𝐻𝑇
                 Eq. 3.2 
According to the OECD Test Guideline (OECD, 2004)35 a chemical is 
predicted as phototoxic if PIF is > 5, probably phototoxic if PIF > 2 and 
< 5, and non-phototoxic when PIF < 2. Sodium dodecyl sulphate (SDS) 
was used as negative control and lomefloxacin (LFX) was used as an 
established phototoxic reference compound.19,21 
3.4.8. Cellular localization studies by confocal microscopy 
Firstly, FSK cells were seeded on glass coverslips in 24 well-plates 
(5.0 x 104 cells/well). Next day, DMEM medium was replaced by 500 µL 
of compound solutions (LFX, 1 and 2) at 200 µM and incubated for 2 h 
at 37ºC. Then, coverslips were washed once for 5 min with PBS and 
finally mounted using Mowiol. Microscopy and imaging were 
performed with a Leica SP5 confocal microscope (Leica, Germany) using 
sequential mode. Representative images were selected from at least 
three different regions on the slide.  
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Chapter 4. Effects of fluoroquinolones 









Fluoroquinolones (FQ) are quinolinic derivatives with an aminoalkyl 
substituent (Chart 4.1). They are widely used as antibacterial agents 
because they develop their pharmacological activity through the 
inhibition of Topoisomerase II, a bacterial enzyme involved in the 
replication and repair of bacterial DNA. 1 A large number of studies 
about the effect of the structural modifications of FQs on the 
antimicrobial activity of this type of drugs have been conducted.2 Thus, 
it has been observed that modifications on positions 1, 2 , 5, 7 and 8 of 
the quinolinic ring affect the antimicrobial  activity of FQs and 
consequently their affinity to biomolecules. In this context, most of the 
modifications also affect the photochemical and photobiological 
properties associated to these drugs.3 During the last years FQ have 
raised much attention due to their antitumoral activity.4–8 In vitro and 
in vivo studies have confirmed anti-cancer effects of quinolone 
antibiotics supporting the observation that FQs reduce all-cause 
mortality among cancer patients.9 The direct anti-tumor effect of FQs 
has also been associated with the inhibition of mammalian enzymes 
such as deoxyribonucleic acid topoisomerase I, topoisomerase II and 
DNA polymerase. Interestingly, the genotoxic effects exhibited by FQs 
in eukaryotic systems are enhanced by UV irradiation,10 which confers 
to these type of drugs a potential property as photochemotherapeutic 
agents. In fact, photoinduced genotoxicity has remarkably been 
detected in 6,8-dihalogenated FQs such as fleroxacin, BAY y3118 and 






Chart 4.1).11–17 Moreover, it has been clearly observed that these drugs 
also produce photoxicity and photoallergy.18,19 Thereby, a large number 
of studies concerning the  photochemical  and photobiological 
properties of FQs bearing a further halogen atom at position 8 of the 
quinolinic ring have been carried out during the last few years.14–26 All 
of them have shown an unusual photodehalogenation by heterolysis of 
the strong C8-halogen bond from the triplet excited state of FQ (3FQ) 
leading to the generation of an aryl cation with alkylating properties.20–
26 However, other intermediates can also be generated when 
dihalogenated fluoroquinolones  are associated with biomolecules.21,22 
Several processes can be involved in the photosensitized biomolecular 
damage  produced by FQs. Thus, photooxidation of DNA is the main 
damage caused by its association with FQs, while in proteins, such as 
albumin, a photobinding occurs between the protein and the FQ. 21,22 
A recent study designed a new 6,8 dihalogenated quinolone 1 ( 1-
methyl-6,8-difluoro-4-oxo-7-aminodimethyl-1,4-dihydroquinoline-3-
carboxylic acid) for improving the phototoxic properties of 
fluoroquinolones by increasing the alkylating properties of the 
quinolinic structure.27 However, although this property was clearly 
proved  and correlated with a higher phototoxic effect than those 
observed for close related FQs, the affinity of these compounds to 
biomolecules was not evaluated and their knowledge could allow to 
design new compounds with improved phototoxic effects.  With this 
background, the aim of the present study is to analyze the effect of 






4.1 LFX, ACLFX, compound 1 and 2) which can modify their binding 
affinity to biomolecules and consequently, the photochemical 
processes involved in their phototoxic effects. 
 
Chart 4.1. Chemical structure of dihalogenated FQs 
4.2. Results and discussion 
4.2.1. Study of the interactions between FQ and biomolecules using 
emission measurements 
Fluorescence lifetimes of FQs were registered at λex 350 nm (an 
isosbestic wavelength of their absorption spectra with increasing 
amounts of DNA) with and without the presence of DNA (10-3 M in 
nucleotide) to evaluate the possible involvement of a dynamic 
quenching in their emissions. Hence, the emission lifetimes of LFX, 
ACLFX, 1 and 2 were 1.2, 1.4, 1.2 and 1.3 ns respectively and they do 
not show any change by the presence of DNA. These results, in 






discard any dynamic fluorescence quenching process. Moreover, the 
static emission quenching of FQs was also analyzed to determine the 
possibility of binding of FQs to DNA. The evolution of emission spectra 
of aqueous solutions of each FQ in the presence of different DNA 
quantities showed low emission decreases for all compounds. Figure 
4.1 displays the fluorescence spectra obtained for compound 1 and 2.  
Thus, the Ksv for each FQ was calculated from Equation 4.1 assuming 
that the FQ complexed to DNA (FQ…DNA) does not emit. Results are 
shown in Table 4.1. The equilibrium constants for the complex 
formation estimated for LFX…DNA and for ALFX…DNA were similar to 
those described in the literature. In this context, compound 2 showed 
a Stern-Volmer constant (Ksv) very similar to that obtained for ACLFX 
while a very low Ksv value obtained for 1 evidenced the absence of any 
type of complexation between DNA and 1. Consequently, polarity 
decreases of the FQs, such as the N(4’)-acetylation of the piperazinyl 
ring or the absence of this substituent, diminishes FQ affinity to DNA. 
Interestingly, the absence of complexation observed for 1 would be 
attributed to the change of an ethyl at the N(1) position of the 




































Figure 4.1. Fluorescence quenching of 2 by the presence of different amounts 
of DNA (molar concentrations of nucleotides) in aqueous media. Inset: Effect 
of increasing amounts of DNA in the fluorescence of 1 under similar conditions.  
Table 4.1. Stern-Volmer constants of biomolecules (DNA, HSA) with FQs in 
neutral aqueous media (PB 1 mM) and percentage of HSA-FQ photoadduct 
generated in the irradiations of aqueous solutions of FQ in HSA. 
 
 1 2 ACLFX LFX 
DNAa 
KSV (M-1) 
>30 332 435 1300 
HSAb 
KSV (M-1) 
4.1 x 104 4.8 x 104 
4.8 x 104 
(1 x 104)a 
2.3 x 103 
(2.6 x 103)a 
PHOTOADDUCT 
HSA-FQ (%) 
11 + 1 7 + 1 5 + 1 1.5 + 1 
 
a; Values determined from FQ fluorescence quenching by biomolecules. b; 
Values determined from HSA fluorescence quenching by FQs. 
 
 
































FQs fluorescence quenching by HSA was carried out by addition of 
albumin (up to 10-4 M) to 7.5 x 10-5 M FQ solutions using λex 310 nm (it 
is an isosbestic wavelength of the absorption spectra of FQ with 
increasing amounts of HSA) with the aim of determining more 
accurately the HSA…FQ binding constants. Figure 4.2 shows the results 
of the FQs fluorescence intensities adding different amounts of 
albumin. As expected for ACLFX, its emission is quenched more 
efficiently than that of LFX.28 By contrast, the effect observed for 
compounds 1 and 2 was a blue shift of their emissions, which indicates 
that they are also associated with albumin but without a clear 
interaction between the singlet excited state of these FQs because 







emission quenching of compounds 1 and 2 by HSA does not apparently 
occur. In this context, fluorescence lifetime (τF) of all FQs did not show 
any change by the addition of 10-4 M HSA. Thus, the static fluorescence 
quenching observed for LFX and ACLFX can only be attributed to the 
singlet excited state reactivity of LFX and ACLFX (1LFX and 1ACLFX) with 
albumin when this FQs are associated with HSA because there is not 
any involvement of a dynamic process in the emissions quenching of 
both FQs. Contrarily, 11 and 12 do not react with albumin although 
FQs…HSA complexes are also formed. With these results and assuming 
that the LFX and ACLFX bounds to HSA do not emit, Ksv was only 
determined for the formation of the complex between HSA and LFX or 
ACLFX as a simple model to obtain their association constants (Ka). 
These values, shown in Table 4.1, were obtained using Equation 4.2 and 
they are in agreement with data of the literature.21,29 
In this context, emission quenching of the Trp unit present in HSA is 
often used to obtain information about FQ…albumin associations. The 
Trp fluorescence band is centered at ca. 344 nm and it is exclusively 
exhibited by albumin after excitation at 295 nm.30 Hence, the 
experiments were performed using 10-5 M HSA in aqueous solutions 
(10-3 M PB, pH ca. 7.4) by adding different amounts of FQ (between 10-
6 and 1.2 x 10-5 M). Correction for the inner filter effect (IFE) was applied 
before analysis of the results because the FQs show absorption at the 


























Figure 4.3. Stern-Volmer plots of HSA fluorescence versus FQs. 
The Ksv of the experiments were calculated from the slope of the 
plot F0/F versus [Q] of Figure 4.3. Results showed in Table 4.1 and Figure 
4.3 revealed that the interactions between HSA and FQs such as ACLFX 
or 1 or 2 are higher than those produced between HSA and LFX. In static 
quenching processes, the Ksv values correspond to the total association 
constant of quencher to the protein when the quencher totally 
suppresses the intrinsic protein fluorescence.31 Therefore, the resulting 
Ksv are a good approximation for FQ…albumin association constants.32 
It was established that N-acetylation of LFX produces an increase in 
the affinity predominantly for site II,22 which could also be occurring for 
1 and 2. Moreover, these results are also fully consistent with the 






ring) for site II of HSA.33 In fact, it is reasonable that a cationic 
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Figure 4.4. Decay traces of LFX at 490 nm in the presence of different 
concentrations of HSA under anaerobic (N2O) aqueous media. Inset; Transient 
absorption spectra of LFX aryl cation generated after the laser pulse at 355 nm 
under anaerobic (N2O) aqueous media. 






























































Figure 4.5. Decay traces of ACLFX at 600 nm in the presence of different 
concentrations of HSA under anaerobic (N2O) aqueous media. Inset; Transient 
absorption spectra of ACLFX aryl cation generated after the laser pulse at 355 
nm under anaerobic (N2O) aqueous media. 






















































Figure 4.6. Decay traces of 1 at 480 nm in the presence of different 
concentrations of HSA under anaerobic (N2O) aqueous media. Inset; Transient 
absorption spectra of 1 aryl cation generated after the laser pulse at 355 nm 
under anaerobic (N2O) aqueous media. 


























































Figure 4.7. Decay traces of 2 at 490 nm in the presence of different 
concentrations of HSA under anaerobic (N2O) aqueous media. Inset; Transient 
absorption spectra of 2 aryl cation generated after the laser pulse at 355 nm 
under anaerobic (N2O) aqueous media. 
4.2.2. Reactivity of FQ aryl cations with HSA 
In agreement with the literature, when photolysis of aqueous 
solutions of LFX and ACLFX, 1 and 2, were performed at pH = 7.4 under 
N2O, generation of aryl cations of LFX (λmax = 490 nm and τ ca. 200 ns), 
ALFX (λmax = 600 nm and τ ca. 340 ns), 1 (λmax = 480 nm and τ ca. 3.1 μs) 
and 2 (λmax = 480 nm and τ ca. 300 ns) were registered.23–25,27 
Decays traces and transient absorption spectra of all of them are 
shown in Figures 4.4, 4.5, 4.6 and 4.7. Laser excitation of FQs (10-4 M) 
in 1 mM PB solutions (10-4 M, pH ca. 7.4) under N2O atmosphere 

































displayed the same transient absorption species in the absence and the 
presence of HSA (up to 10-4 M). The aryl cations lifetime of LFX and 
ACLFX remained nearly unaltered. However, the generation of these 
intermediates resulted to be lower when HSA was added, being this 
effect the most important for the ALFX aryl cations (see the absorption 
of the decays in Figure 4.4 and 4.5). In the case of 1 and 2 this effect 
was not observed but changes in the lifetime of their aryl cations were 
detected (see Figure 4.6 and 4.7).  
The observed absorption of LFX and ACLFX aryl cations decreases at 
its λmax by addition of HSA, which can be understood considering this 
biomolecule-drug equilibrium:  
 
in Equation 4.1: 
Ka = [FQ…HSA] / ([HSA] x [FQ])                              Eq. 4.1 
Thus, applying the Ka determined for ACLFX and LFX by fluorescence 
quenching in equation 4.1, and assuming the reactivity of 1ACLFX and 
1LFX with albumin, can be understood the decrease in the generation 
of the corresponding to their aryl cations. In the case of 11 and 12, as 





















































Figure 4.8. Absorption spectra of FQs aqueous solutions in the presence of HSA 
(1/1) after Sephadex chromatography. 
4.2.3. Covalent binding of FQs to HSA 
Formation of adducts between HSA and FQs was detected when the 
corresponding photomixtures were analyzed after gel filtration with 
Sephadex using UV-Vis spectrometry. Filtered samples of HSA obtained 
from irradiated solutions (2 and 4 minutes) of FQs in the presence of 
albumin showed changes in their absorption spectra (results are shown 
in Figure 4.8). The filtered samples of control experiments (no light) 
with only (A)LFX or HSA showed no absorption from 300 nm to 400 nm 
in any case. The amount of FQ-albumin adducts produced during the 














































irradiation time of each FQ solution in the presence of HSA was 
determined from their corresponding absorption spectra. Results, 
shown in Table 4.1, revealed that 1 photobinding is more efficient for 
those detected for 2 and ACLFX. The photobinding obtained for LFX was 
the lowest. These results would be correlated with two previous 
findings: a) the Ka values determined for the FQs with HSA (table 4.1), 
where there is very low association between LFX and HSA and b) the 
reactivity detected in the laser flash photolysis experiments for the 
singlet excited state of ACLFX and the aryl cations for 1 and 2 with 
albumin. Thus, as it can be observed in Figures 4.4-4.7, while the 
presence of albumin in the aqueous samples of LFX did not produce any 
change in its decay traces, an absorption decrease in the ACLFX decay 
traces and fast decay traces for 1 and 2 was observed using the same 
experimental conditions with ACLFX, 1 and 2. 
 
Figure 4.9. Phototoxicity of LFX in the 3T3 NRU Assay. 3T3 cells were treated 
with serial dilutions of LFX or related compounds for 1h, followed of a 5 J/cm2 






as a negative control. IC50 values were calculated by non-lineal regression with 
GraphPad Prism 5.0. Data represent Mean±SD from four independent 
experiments and asterisks correspond to significant differences relative to the 
IC50 LFX by the T-Student test (**p<0,01; ***p<0,001; Ns: non-statistically 
significant.). 
 












>500 543 348 53 
ACLFX 
>500 >500 >500 153 
1 
>500 270 192 19 
2 
>500 311 283 66 
 
4.2.4. Phototoxic properties of FQs 
Cell viability upon incubation with LFX, ACLFX, 1 and 2 in 
combination with UVA light was assessed by the in vitro 3T3 NRU 
phototoxicity test. Cytotoxicity profiles of BALB/c 3T3 fibroblasts 
treated with FQs were measured in the presence and absence of UVA 
light, using neutral red as vital dye, and half maximal inhibitory 
concentration (IC50) were determined from dose-response curves. 
Different light doses were tested in this study and the results are 






The effect observed for 1 was higher than LFX, and 2 (a 3-fold increase 
of the IC50 was determined) while in the case of ACLFX, its phototoxicity 
is very low. Different behaviors must be involved in the phototoxic 
assays. Noteworthy, the N-alkyl chain at the position 1 of these type of 
fluoroquinolones is a small structural modification with a great 
influence because the phototoxicity of 1 is the highest. However, the 
lowest phototoxic effect observed for ACLFX and the results obtained 
using 2 and LFX can not be easily explained because ACLFX is 
structurally more related to LFX than 2 with LFX and ACLFX and 2 have 
acidic properties, while LFX has an amphoteric character. Moreover, it 
has been observed that this type of fluoroquinolones showed similar 
cytoplasmic localization in human cells.27,34 Nevertheless, the 
phototoxic effect observed in the FQs of this study could be understood 
combining the affinity of these compounds to biomolecules such as 
DNA and or proteins and the reactivity of their photo-generated 
intermediates with their target biomolecules. Hence, although the four 
FQs under study show the same intermediates, mainly singlet and 
triplet excited states and aryl cations and radicals, they showed 
different affinity to DNA and HSA and in the case of 1 and 2, different 








Scheme 4.1. Photochemical process involving the phototoxic effects observed 
for LFX, ACLFX, 1 and 2. 
Thus, the most phototoxic compound 1, which has a high affinity for 
albumin, must react efficiently with proteins via its aryl cation because 
it does not react with albumin from its 11 and cannot generate 
photoproducts by an intramolecular reaction described for the other 
dihalogenated FQs.27 Thereby, although compound 2 has the same 
affinity than 1 to proteins such as HSA, its phototoxic effectivity  can 
decrease because it can be photode  gradated via pathway IV. In the 
case of ACLFX, which shows the lowest phototoxicity but has the same 
affinity to HSA than that detected for 2 and also a similar 
photodegradation pathway, a back electron transfer process of the 
reaction of its singlet excited state with any reactive amino acid of HSA 
could explain the results obtained. In fact, ACLFX showed different 
location in albumin, and consequently, the involvement of route I in its 
photochemical processes. The phototoxicity observed for LFX could be 






to DNA and it is known that the back electron transfer process in these 
biomolecules is a minor pathway.22 
4.3. Conclusion 
To understand the phototoxic effects produced by FQs it is 
necessary to evaluate their reactivity with biomolecules as well as their 
affinities. Thereby, as it has been done for the antibacterial activity of 
FQs, a deep study about the structure-activity of the phototoxic 
properties of FQs would be needed to enhance the phototoxic potential 
of FQ in order to obtain drugs with more photochemotherapeutic 
properties. 
4.4. Experimental section 
4.4.1. Materials 
Calf thymus DNA, Human serum albumin fatty free (HSA) and 
lomefloxacin (LFX) were commercial products obtained from Sigma-
Aldrich while plasmid prB322 was supplied by Roche and Sephadex G-
25 columns by GE Healthcare. Sodium phosphate buffer (PB) was 
prepared from reagent-grade products using milli-Q water; the pH of 
the solutions was measured through a glass electrode and adjusted 
with NaOH to pH 7.4. 
4.4.2. Synthesis of FQs 
Acetyl LFX (7-(4-acetyl-3-methyl-1-piperazinyl)-1-ethyl-6,8-difluoro-






previously described from a solution of LFX (300 mg, 0.9 mmol) in acetic 
anhydride (50 mL) that was refluxed for 7 h.23 
1-Methyl-7-dimethy1amino-6,8-difluoro-1,4-dihydro-3-
quinolinecarboxylic acid (1) and 1-Ethyl-7-dimethy1amino-6,8-difluoro-
1,4-dihydro-3-quinolinecarboxylic acid (2) were prepared as previously 
described.35,36 
4.4.3. Absorption and emission measurements 
Ultraviolet spectra were recorded on a UV/Vis scanning 
spectrophotometer (Cary 50). Fluorescence emission spectra were 
recorded on a Photon Technology International (PTI) LPS-220B 
fluorimeter. Lifetimes were measured with a time resolved 
spectrometer (TimeMaster fluorescence lifetime spectrometer TM-
2/2003) from PTI by means of the stroboscopic technique, which is a 
variation of the boxcar technique. A hydrogen/nitrogen flashlamp (1.8 
ns pulse width) was used as excitation source. The kinetic traces were 
fitted with monoexponential decay functions. Measurements were 
made under aerated conditions at room temperature (25 °C) in 
cuvettes of 1 cm path length. The excitation wavelength used to 
register the fluorescence lifetimes was 320 nm. The fluorescence 
quantum yield of quinine bisulphate in 1 N H2SO4 (φF = 0.546) was used 
as a standard. 
4.4.4. Fluoroquinolone fluorescence quenching by DNA 
The experiments were performed using 10-4 M FQ buffered aqueous 






(there is an isosbestic wavelength). The DNA concentrations were 
determined spectrophotometrically taking into account a molar 
extinction coefficient ε=258 nm = 6700 cm-1 M-1.37,38 Equation 4.2 was 
selected to determine the drug-DNA interactions from fluorescence 
quenching data:31,32,39–41 
F0/F = 1+ Ksv [Q]                  Eq. 4.2 
where F0 and F are the fluorescence intensities in the absence and 
presence of the quencher respectively, [Q] is the quencher 
concentration (DNA from 10-5 to 1.5 x 10-3 M in nucleotide) and Ksv is 
the Stern-Volmer quenching constant. 
4.4.5. Fluorescence quenching of fluoroquinolones by albumin 
This fluorescence quenching study was performed by adding HSA 
concentrations from 10-5 to 10-4 M FQ buffered aqueous solutions (10-
3 M PB, pH ca. 7.4) after excitation at 310 nm (there is an isosbestic 
wavelength). These data were also analyzed using the equation 4.2 to 
establish the drug-biomolecule interactions. 
Equation 4.2 was selected to determine the drug-protein 
interactions from the fluorescence quenching data:42–46 
4.4.6. Albumin fluorescence quenching by fluoroquinolones 
Experiments were performed with phosphate buffered (10-3M, pH 
ca 7.4) aqueous solutions containing 10-5 M HSA. Thus, HSA displays a 
fluorescence band centered at 344 nm, after excitation at 295 nm. The 






increasing the amounts of FQs under study (from 10-6 to 1.2 x 10-5 M). 
Before analyzing the data, the so-called inner filter effect correction 
(IFE) was applied because both FQ absorb light at the excitation and 
emission wavelengths. The IFE correction was applied using equation 
4.3:42,47,48 
Fcorr = Fobs x 10 (Aex+Aem)/2                  Eq. 4.3 
where Fcorr and Fobs are the corrected and observed fluorescence 
intensities respectively, and Aex and Aem are the absorbance values at 
the excitation and emission wavelengths, respectively. 
4.4.7. Laser flash photolysis experiments 
A pulsed Nd:YAG laser system was used for the excitation at 355 nm. 
The single pulses were ~10 ns duration and the energy was from 15 to 
5 mJ/pulse. A pulsed xenon lamp was employed as detecting light 
source. The laser flash photolysis apparatus consisted of the pulsed 
laser, the Xe lamp, a monochromator and a photomultiplier made up 
of a tube, housing and power supply. The output signal from the 
oscilloscope was transferred to a personal computer. 
Aqueous solutions of 10-4 M FQs were prepared in 10-3 M PB and the 
experiments were registered under anaerobic conditions by bubbling 
N2O. Transient absorption spectra at different times after the laser 
pulse were obtained for each sample in the presence and the absence 
of biomolecules, paying special attention to intersystem crossing 






The DNA concentrations ranged between 10-4 and 10-3 M in nucleotides 
and HSA concentration from 10-5 to 10-4 M. 
The quenching experiments were carried out keeping the pH 
constant at 7.4 throughout the experiment.  
Rate constants of aryl cations quenching by biomolecules were 
determined using the Stern-Volmer equation 4.4: 
1/τ = 1/ τ0 + k [Quencher]                  Eq 4.4 
4.4.8. Analysis of the covalent binding of fluoroquinolones to HSA 
induced by light 
The study was performed using 1/1 molar ratio of drug/protein for 
UV-Vis measurements. FQs were added to 10-4 M HSA and allowed to 
incubate in the dark for 30 minutes. Photolysis was performed using a 
Rayonet photochemical reactor equipped with six black light phosphor 
lamps emitting in the 310-390 nm range, with a maximum at ca. 350 
nm. Samples were then irradiated during 120 seconds UV time periods 
(with a light doses of ca. 280 mJ/cm2) and then kept in the darkness 
during 24 hours prior to analysis (controls included drug-HSA mixtures 
kept in the dark, HSA with and without irradiation and irradiated drug 
added to HSA). The samples were diluted by a factor of two by adding 
water before the protein separation. Subsequently, to determine 
whether FQ is covalently linked to HSA, the solutions were 
chromatographed on Sephadex G-25 columns equilibrated with 2/8 
ethanol/aqueous 10 mM PB, as described previously.41 The first fraction 






while in the second one there was the remaining free drug. Thus, the 
first fraction was analyzed by UV-Vis spectrometry to determine the 
amount of drug linked to albumin from the absorption spectra of these 
samples. 
4.4.9. In Vitro 3T3 neutral red uptake (NRU) phototoxicity test 
BALB/c 3T3 fibroblasts cell line was grown in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with 4 mM glutamine, 1% 
penicillin/streptomycin 10% and Fetal Bovine Serum (FBS) and routinely 
maintained in exponential growth in 75 cm2 plastic flasks in a 
humidified incubator at 37°C under 5% carbon dioxide atmosphere. The 
3T3 Neutral Red Uptake Phototoxicity Test was performed as described 
by the OECD guideline 432 (OECD, 2004) with minor modifications.49,50 
Briefly, two 96-wells plates (2.5 × 104 cells/well) were seeded for each 
compound. Cells were treated with compounds FQs and SDS at several 
concentrations ranging from 0.5 μM to 500 μM and incubated for 1 h. 
Afterwards, one plate was irradiated on ice for 11 min to achieve a dose 
of UVA equivalent to 5 J/cm2 (UVA LIGHT), whereas the other plate was 
kept in a dark box (DARK). The viability of UVA-treated control cells in 
the absence of test compounds was > 90% of those kept in the dark 
indicating the suitability of the UV dose. After irradiation, the 
compound solutions were replaced with DMEM medium, and plates 
were incubated overnight. Subsequently, neutral red solution (50 
μg/mL) was added into each well and incubated for 2 h. Cells were 
washed with PBS and neutral red was extracted in 100 μL with the 






(v/v). Then, the absorbance was measured at 550 nm on a Multiskan Ex 
microplate reader. For each compound dose-response curves were 
established in order to determine the concentration of compound 
producing a 50% reduction of the neutral red uptake (IC50) in the dark 
and light. In the end, Photo-Irritation-Factor (PIF) was determined using 
the following equation:  
PIF = IC 50 DARK/IC 50 UVA LIGHT                Eq. 4.4 
According to the OECD Test Guideline (OECD, 2004)50 a chemical is 
predicted as phototoxic if PIF is > 5, probably phototoxic if PIF > 2 and 
< 5, and non-phototoxic when PIF < 2. Sodium dodecyl sulphate (SDS) 
was used as negative control and lomefloxacin (LFX) was used as an 
established phototoxic reference compound.17,51 
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Chapter 5.  Studies of fluoroquinolone 









Fluoroquinolones (FQs) were first discovered in 19801 and used as 
antimicrobial agents due to their pharmacological activity based on the 
inhibition of topoisomerase II, an enzyme which plays a key role in the 
replication and repair of bacterial DNA.2 In the last years, some of the 
components of this family of quinolones have gained interest as 
antitumoral drugs acting in the replication of DNA by inhibiting DNA 
polymerase, topoisomerase I and topoisomerase II.3–6 Several studies 
demonstrate that this genotoxic effect is enhanced by ultraviolet (UV) 
irradiation converting the FQs in proper photochemotherapeutic 
agents.7 Photochemical and photophysical properties of 6,8-
dihalogenated FQ have been deeply studied in the presence and 
absence of biomolecules. Unusual heterolysis of C8-halogen bond 
generates an aryl cation with alkylating properties, which has been 
proposed as the origin of the most important FQ side-effects.8–12 
Several studies have associated the formation of reactive intermediates 
in the photodehalogenation process with the FQ photosensitivity.8–14 
Interestingly, decreasing the peripheral substituents size has recently 
been shown to improve the efficiency of intermolecular reactions 
between biomolecules and FQs due to the lack of intramolecular 
reactivity of a carbene intermediate with their substituents.15 Thereby, 
when the phototoxic properties of lomefloxacin (LFX) were compared 
with 1 and 2 in vitro 3T3 NRU phototoxicity test (see structures in Chart 
4.1), the Photo-Irritation-Factor (PIF) of 1 resulted to be more than 






demonstrated that the photochemotherapeutic properties of 
antitumor quinolones could be improved by using this structural 
modification.15  It has also been evidenced that the intermediate 
responsible for the phototoxic properties associated with 
dihalogenated quinolones is the aryl cation.  
Nanomedicine has emerged as a new branch to solve the 
shortcomings of current treatments by designing new materials.16 An 
extensive range of nanomaterials has been developed during the last 
decades as therapeutics either for cancer or other diseases.16–18 An 
example of those new materials are the upconversion nanoparticles 
(UCNP) which have the capability of converting near infrared light (NIR) 
into UV, Visible (Vis) or NIR emission in an anti-Stokes process.19 They 
have gained interest over the past years due to their advantages such 
as high signal/noise ratio, low toxicity and higher penetration in tissue 
of NIR light for several applications like bioimaging, drug release, laser 
design or solar cells among others. 20–26 In this context, several UCNP 
materials have also been deeply studied for photodynamic therapy 
(PDT), which uses a combination of special drugs and UV light to treat 
cancerous. Thus, cancer cells death have been observed by using UCNP 
cores with shells containing different types of photosensitizers. 
Thereby, by applying NIR to this type of nanomaterials an activated 
oxygen specie (singlet oxygen) is generated, which is able to oxidize 
biomolecules of the cells. 27–31  
With this background, the to design of a new nanomaterial for 






Vis-NIR light and the alkylating properties of some type of 
fluoroquinolones was proposed. Thereby, the new nanohybrids will 
attack the cells as alkylating bombs. 
The design of the new material will be composed of UCNP (NaYF4: 
Yb/Tm (20%, 0.5%)@NaYF4) as core and the most phototoxic FQ 
(compound 1) as shell together with succinic acid (SA). 
5.2. Results and discussion 
5.2.1. Synthesis and characterization of upconversion nanoparticles 
(UCNP) 
 







Scheme 5.2. Synthetic route to obtain NaYF4: Yb/Tm@NaYF4@1-SA 




 Absorption of 1

































Figure 5.1. Absorption spectrum of 1 and emission spectrum of NaYF4: Yb/Tm 
(20%, 0.5%)@NaYF4 2mg / mL at desired region. Inset: complete emission 
spectrum of NaYF4: Yb/Tm (20%, 0.5%)@NaYF4 (black) and NaYF4: Yb/Tm (20%, 
0.5%) (red). λex = 980 nm 
NaYF4: Yb/Tm 20%, 0,5%) nanoparticles were selected as the base 
of the nanosystem due to their particular characteristics. On one hand, 
they are able to absorb in the NIR region ( 980 nm) and emit at shorter 
wavelengths avoiding direct irradiation with harmful UV light. On the 
other hand, due to their specific composition, with Thulium and Yttrium 
as dopants, they have an emission peak ca. 362 nm being a good 
candidate to excite our studied drug 1 (see Figure 5.1).19,32  























NaYF4: Yb/Tm (20%, 0,5%) nanoparticles need more than two photons 
due to their high space between energetic levels. For that reason, 
NaYF4: Yb/Tm (20%, 0,5%) @NaYF4 core/shell nanoparticles have been 
synthesize achieving higher emission in the region of interest (see inset 
of Figure 5.1)33–35  
First of all, upconversion nanoparticles were synthesized via 
Ostwald Ripening method (more details in experimental section). As 
second step, a shell made of NaYF4 was grown in order to protect the 
NaYF4: Yb/Tm core from the future hydrophilic media and, in addition, 
to achieve higher emission bands. This nanosystem was going to be 
studied in vitro, so nanoparticles need to have a hydrophilic shell which 
make them water soluble. Different types of hydrophilic shells have 
been described in the literature.33,35–37 In this case, the nanosystem has 
been covered with succinic acid by ligand exchange (see Scheme 5.1). 
This type of reaction allows in one-step cover change and drug loading.  
After each step of the synthetic route (Scheme 5.2), nanoparticles 
were characterized by X-ray diffraction system and transmission 
electron microscopy (see Figure 5.2 and 5.3). β- NaYF4 crystal can be 
observed in Figure 5.3 X-Ray as compared with the refence. The 
obtained core/shell nanoparticles have a size of 21 ± 2 nm. NaYF4: 
Yb/Tm (20%, 0.5%) nanoparticles were less regular in size (17 ± 2.5 nm) 








Figure 5.2. a) TEM image of NaYF4: Yb/Tm (20%, 0,5%) @NaYF4 b) Histogram 
of distribution size 
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Figure 5.3. a) X-ray spectrum of NaYF4: Yb/Tm (20%, 0,5%) @NaYF4 b) Standard 
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Figure 5.4. Absorption spectrum of NaYF4: Yb/Tm (20%, 0.5%) @NaYF4 2 mg/ 
mL in cyclohexane and NaYF4: Yb/Tm (20%, 0.5%) @NaYF4 @1-SA 2mg / mL in 
cell media. Inset: NaYF4: Yb/Tm (20%, 0.5%) @NaYF4 @1-SA 2 mg / mL in DMSO 
The ligand exchange of oleic acid (OA) by SA and 1 was performed 
using different proportions between SA and 1 (see experimental 
section below). High amount of 1 resulted in high 1 concentration 
loaded in the system but low hydrophilic nanoparticles (see inset of 
Figure 5.4). After several trials with different SA-1 proportions, the 
selected ones were the specified in experimental section and Figure 
5.4. There was high light scattering in the samples resulting in an 
increase of the base line from 550 nm, which was subtracted for 
determining 1 concentration in the solutions of nanoparticles.  An 
approximation of the number of molecules of 1 contained in a 






















sphere of 20 nm of diameter and between 10-15 molecules of 1 are on 
the surface of a nanoparticle. 
Concerning the stability of the nanoparticles under study, it was 
observed that their stability in aqueous media was low. Hence, it was 
observed that the nanoparticles were completely dissolved in aqueous 
media in two weeks. In fact, our nanosystem showed small 
deformations or cracks only 48 h after the complete preparation (see 
in Figure 5.5 TEM images of NaYF4: Yb/Tm (20%, 0.5%) @NaYF4 @1-SA 
system after 48 h in aqueous media). 
 
Figure 5.5. TEM image of NaYF4: Yb/Tm (20%, 0.5%) @NaYF4 @1-SA system 
after 48 h 
5.2.2. Photolysis of 1 in aqueous solutions with nanosystem 
NaYF4:Yb(20%)Tm (0.5%) @NaYF4@1-SA 
As a way to detect the generation of the alkylating intermediates 
(aryl cations, see mechanism in Scheme 3.3), photolysis of 1 was 
analyzed by measuring  fluoride anion release (details in experimental 






NaYF4:Yb(20%)Tm(0.5%)@NaYF4 @1-SA in aqueous medium (2.5 mL of 
nanoparticles 2mg/mL containing 1 2 x 10-5 M ) using  an infrared laser 
RLTMDL-980 1-2000 mW (PSU-III-LED) at λmax = 980 nm ± 5 nm and a 
laser energy of ca. 2000 mW/cm2 showed that 1 x10-5 M of fluoride 
anion had been released after the first 5 min of the irradiation and this 
value increased till 1.5 x 10-5 M after 10 min.  Thereby, it was proved 
that the irradiation of NaYF4: Yb (20%), Tm (0.5%) @NaYF4 @1-SA with 
a laser at 980 produces the photolysis of 1 with the consequent release 
of fluoride anion and the generation of its aryl cation (mechanism 
details shown in previous chapters).  
5.2.3. Cell viability assay of NaYF4: Yb/Tm@NaYF4@1-SA 
The nanosystem for the cell viability assays contained 2.5 μM 1 in 2 
mg of nanoparticles/ mL. Hence, after drug loading and hydrophilic 
surface achievement, HELA cells were treated with NaYF4: 
Yb/Tm@NaYF4@1-SA. A 24-hour incubation was carried out to ensure 
the entry of the nanosystem into the cell.38 After incubation time, cells 
























Figure 5.6. Cell viability of HELA cells after irradiation with NaYF4: 
Yb/Tm@NaYF4@1-SA (NPs) and without them (CN) at different irradiation 
times using a laser at 980 nm (5, 10 and 15 min). 
These assays showed great results because the cell viability after 10 
min of irradiation was only ca. 60 % and ca. 50 % after 15 min. Thus, 
the IC50 was achieved using only solutions of 2.5 μM, a value that is 
more than 6 times lower than that obtained using UVA irradiations of 
homogeneous solutions of compound 1 (IC50 ca. 16 μM (see page 70 in 
Chapter 3)). Hence, it was observed that the expected alkylating bombs 
increase the phototoxical properties of 1.  
5.3. Conclusions  
The high phototoxic capacity observed for compound 1 was improved 
using nanosystems loaded with this molecule. The concept of an 






nanoparticles and near infrared light. This increase of the described 
adverse effect of FQs could be used as a photochemotherapeutic 
property to destroy tumor cells. 
5.4. Experimental section 
5.4.1. Materials  
Yttrium (III) chloride (YCl3), Ytterbium (III) chloride (YbCl3), Thulium 
(III) chloride (TmCl3), oleic acid (OA), 1-octadecene (ODE), ammonium 
fluoride (NH4F), sodium hydroxide (NaOH), and human serum albumin 
were commercial products obtained from Sigma-Aldrich Chemical 
Sodium phosphate buffer (PB) and sodium bicarbonate buffer were 
prepared from reagent-grade products using milli-Q water; the pH of 
the solutions was measured through a glass electrode and adjusted 
with NaOH to pH ca. 7.4. Dulbecco's Modified Eagle Medium (DMEM) 
was commercially obtained from Thermo Fisher. Other chemicals were 
of reagent grade and used as received. 
5.4.2. Synthesis of 1-Methyl-7-dimethy1amino-6,8-difluoro-1,4-
dihydro-3-quinolinecarboxylic acid (1)  
1-Methyl-7-dimethy1amino-6,8-difluoro-1,4-dihydro-3-
quinolinecarboxylic acid (1) was prepared as previously described.15  
5.4.3. Instrumentation 
UV-Vis absorption spectra were registered with a Varian Cary 50 
spectrophotometer. For the characterization of NaYF4: Yb/Tm (20%, 
0.5%)@NaYF4, Transmission electron microscopy JEOL JEM—1010, 






International (PTI) LPS-220B fluorimeter coupled with an infrared laser 
RLTMDL-980 1-2000 mW (PSU-III-LED) were used.  
Fluoride detection was performed with a fluoride selective 
electrode (Crison 96 55 C) 
5.4.4. Synthesis of NaYF4 : Yb/Tm (20%, 0.5%) 28 
The salts YCl3·H2O (0.795 mmol), YbCl3·H2O (0.2 mmol) and TmCl3·H2O 
(0.005 mmol) were mixed with 12 mL of oleic acid (OA) and 30 mL of 
octadecene (ODE) in 100 mL 3-necked flask. The solution was heated 
to 160°C to form a homogeneous solution and then cooled down to 
room temperature under nitrogen flow. Afterwards, 10 mL methanol 
solution containing NH4F (4 mmol) and NaOH (2.5 mmol) were added, 
and the solution stirred for 30 minutes. Vacuum-nitrogen cycles were 
done to help methanol evaporation. Then, the solution was heated to 
310 °C, maintained at this temperature for 2 hours under N2 
atmosphere, and then cooled down to room temperature. The 
resultant nanocrystals were precipitated by the addition of ethanol, 
washed with ethanol three times, collected by centrifugation, and 
finally resuspended in cyclohexane.  
5.4.5. Synthesis of NaYF4: Yb/Tm (20%, 0.5%) @NaYF434 
A procedure similar to that shown above was used. YCl3·H2O (1 
mmol) was mixed with 12 mL of oleic acid (OA) and 30 mL of 
octadecene (ODE) in 100 mL 3-necked flask. The solution was heated 
to 160°C to form a homogeneous solution and then cooled down to 






cyclohexane with NaYF4: Yb/Tm nanoparticles was slowly added. 
Temperature was maintained until complete evaporation of 
cyclohexane. After room temperature achievement, 10 mL methanol 
solution containing NH4F (4 mmol) and NaOH (2.5 mmol) were added, 
and the solution stirred for 30 minutes. Vacuum-nitrogen cycles were 
done to help methanol evaporation. Then, the solution was heated to 
310°C, maintained at this temperature for 2 hours under N2 
atmosphere, and then cooled down to room temperature. The 
resultant nanocrystals were precipitated by the addition of ethanol, 
washed with ethanol three times, collected by centrifugation, and 
finally resuspended in cyclohexane.  
5.4.6. Synthesis of NaYF4: Yb/Tm (20%, 0.5%) @NaYF4 @1-SA 39 
Studies of the photolysis of 1 in the NaYF4: Yb/Tm(20%, 0.5%) 
@NaYF4 @1-SA  nanosystem were carried out adding NaYF4: Yb/Tm 
(20%, 0,5%) @NaYF4 nanocrystals (20 mg) to 2 mL DMSO solution 
containing 30 mg of succinic acid (SA) and 40 mg of 1.  Then, the mixture 
was maintained with magnetic stirring overnigth at room temperature 
to obtain the hydrophilic nanosystem. Afterwards, these nanosystems 
were separated by centrifugation, washed 3 times with DMSO and 
finally dispersed in 10 mL water and analyzed by UV-Vis spectroscopy. 
In the cell assays, for a better aqueous solubility of the 
NaYF4:Yb/Tm(20%, 0.5%) @NaYF4 @1-SA nanosystem, the proportions 
between SA and 1 were modified. Thus, 40 mg 1 and 40 mg SA were 






centrifugation, washed 3 times with DMSO and finally dispersed in 10 
mL DMEM cell media and analyzed by UV-Vis spectroscopy. 
5.4.7. Irradiation of nanosystem NaYF4: Yb /Tm (20%, 0.5%) 
@NaYF4@1-SA 
NaYF4: Yb /Tm (20%, 0.5%) @NaYF4@1-SA was irradiated with an 
infrared laser RLTMDL-980 1-2000 mW (PSU-III-LED) at λmax = 980 nm ± 
5 nm using an energy of 2000 mW/cm2. Fluoride anion release was 
measured with a fluoride selective electrode (Crison 96 55 C). Hence, 
2.5 mL of nanoparticles 2 mg/mL in cell media containing 1 2 x 10-5 M 
were placed in a watch glass and irradiated with the laser at λmax = 980 
nm during 5 and 10 min. Then, each sample was analyzed with the 
fluoride selective electrode (Crison 96 55 C). Dark controls were also 
performed.  
5.4.8. In Vitro HELA phototoxicity test 
HELA cell line was grown in Dublecco’s Modified Eagle Medium 
(DMEM) supplemented with 4 mM glutamine, 1% 
penicillin/streptomycin 10% and Fetal Bovine Serum (FBS) and routinely 
maintained in exponential growth in 75 cm2 plastic flasks in a 
humidified incubator at 37°C under 5% carbon dioxide atmosphere.  
For the phototoxicity test, two 96-wells plates (2.5 × 104 cells/well) 
were seeded. Cells were treated with NaYF4: Yb /Tm (20%, 0.5%) 
@NaYF4@1-SA at 2.5 μM concentration and incubated for 24 h. 
Afterwards, one plate was irradiated on ice for 5, 10 and 15 min with 






nm ± 5 nm using 2000 mW laser power, whereas the other plate was 
kept in a dark box (DARK). The viability of NIR-treated control cells in 
the absence of test compounds was > 90% of those kept in the dark 
indicating the suitability of the NIR dose. After irradiation, the 
compound solutions were replaced with DMEM medium, and plates 
were incubated overnight. Subsequently, MTT (50 μg/mL) was added 
into each well and incubated for 2 h. Cells were washed with PBS and 
MTT was extracted in 100 μL with the desorbs solution (water 49% 
(v/v), ethanol 50% (v/v) and acetic acid 1% (v/v). Then, the absorbance 
was measured at 550 nm on a Multiskan Ex microplate reader.  
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Among the light-responsive organic structures available, photolabile 
protecting groups (PPGs) represent key tools for biological and 
biomedical studies.1 They, which are also called phototriggers, are able 
to mask the biological functions of bioactive messengers, drugs or 
neurotransmitters but a suitable light irradiation then triggers the 
physiological response by releasing the free molecule with remarkable 
temporal and spatial control. Thereby, in the last few years, PPGs have 
been widely used for caging biologically active molecules. In many 
cases, the photorelease of bioactive molecules is used with carriers 
such as biocompatible macromolecules, nanoparticles, proteins and 
nanocomposites. Especially in intracellular drug delivery systems, 
suitable carriers protect drugs from premature degradation, inhibit 
possible toxicities and control drug tissue distribution.2 In this context, 
phototrigger-controlled drug-release nanosystems have been 
developed as promising tools for controlled-release drug delivery in 
tumour therapy. 3,4,5  
In general, although different types of caged biomolecules with a stable 
linkage have been developed for under in vivo conditions, all of them 
use phototriggers absorbing ultraviolet (UV) light to achieve cleavage, 
which is a major drawback because UV light is damaging to cells and it 
has poor penetration due to light scattering and absorbance by intrinsic 
biological chromophores.6 In this context, to promote the application 
in biological areas, two approaches are being developed in designing 






infrared (NIR) light  in a two photon excitation method7 or using 
upconversion nanoparticles8 and the second one is to design 
phototriggers absorbing at longer wavelengths. In this context many 
PPGs such as 2-nitrobenzyl, phenacyl, benzoin, 7-nitroindoline, and 
coumarin derivatives are being modified4,7 to improve their absorption 
spectra. Recently, (Coumarin-4-yl)methyl derivatives based 
phototriggers have attracted much attention due to their photolysis 
efficiencies, long wavelength absorption and efficient fluorescence 
emissions.2 They have been successfully applied to mask biological 
activity in phosphates, carboxylates, sulphates, sulfonates, diols, and 
carbonyl compounds.4 Moreover, amino and hydroxyl functionalities 
have also been protected via carbamate or carbonate linkers.4,9,10 The 
photochemical mechanisms involving the coumarin photocleavage 
have been investigated.11–17  Hence, it has been well established that 
the photolysis of these members of arylalkyl-type PPGs occurs upon 
cleavage of a C–O bond, which generates an anionic leaving group and 
a coumarinyl carbocation that is subsequently trapped by the solvent.12 
In this context, it has been proposed that this trapping reaction 
competes with a recombination of the ion pair-separated state to the 
ground state of the caged compound. Several studies have modified 
the coumarin chromophore and the leaving group to understand the 
different efficiencies observed for this type of photolytic reaction. In 
this way, it has been observed that the efficiency of this process 
depends on the nucleofugality of the leaving group but it can be also 
improved adding electron-donating substituents in the coumarin 






With this background, the  prodrug COU-DCO was synthesized by 
linking a photolabile 7-amino-4-hydroymethylcoumarine chromophore 
(COU) to N-deacetylcolchicine (DCO), an antineoplastic agent,20 via 
carbamate formation (see structure in Figure 6.1) with the aim to 
obtain a photoactivatable drug without the severe toxicity to normal 
tissues associated with colchicine derivatives.21 However, the expected 
cleavage of a C–O bond was not produced when this prodrug was 
irradiated. Hence, an analysis of the photophysical properties of the 
coumarin chromophore COU alone and linked to DCO was performed 
to determine the process causing this unexpected photostability of 
COU-DCO. Thereby, femtosecond and nanosecond transient 
absorption spectroscopy together with steady state and time resolved 
emission techniques were used for this purpose. In this context, as an 
electron transfer process between COU and DCO chromophores could 
produce the inhibition of the photorelease of DCO from COU-DCO, a 
dyad without this possible electron transfer property such as COU 
linked to a phenyl alanine derivative PHA, compound COU-PHA, was 







Scheme 6.1. Structures of COU, DCO, PHA, COU-DCO and COU-PHA. 
6.2. Results and discussion 
6.2.1. Photolysis of COU-DCO and COU-PHA 
Scheme 6.2. Synthesis and photorelease process of COU-DCO and COU-PHA 
Prodrug COU-DCO was synthesized by linking a photolabile 7-amino-






deacetylcolchicine (DCO) , an antineoplastic agent,20 via carbamate 
formation (see Scheme 6.1 and 6.2) with the aim to obtain a 
photoactivatable drug without the severe toxicity to normal tissues 
associated with colchicine derivatives.21 Compound COU-PHA was also 
synthesized using the same procedure (see Scheme 6.2).  Initially, 
photolytic studies were performed using lamps with emission at λmax ca. 
350 nm in an aerobic medium of MeOH/H2O (9/1) to determine the 
capability of both compounds for releasing DCO and PHA. Thus, the 
results of the irradiations evidenced a fast photodegradation of both 
compounds (see Figure 6.1). A complete photodegradation was 
observed for COU-DCO in 15 min, however in the case of COU-PHA, 






Figure 6.1. Photodegradation of a) COU-DCO and b) COU-PHA at λmax ca. 350 
nm in an aerobic medium of MeOH/H2O (9/1) 
However, the photorelease process of the compounds linked to the 
coumarine COU resulted to be very low and very inefficient. Thus, in 
the irradiated medium after 60 min of irradiation, detection of PHA 
released from COU-PHA was lower than 20% and for COU-DCO was not 
observed any amount of DCO in the irradiated sample. Nonetheless, 
these irradiations clearly evidenced the transformation of the DCO 































linked to COU in a deacetillumicolchicine DLC, which is a compound 
formed from a cycloisomerization of the tropolone ring, which usually 
occurs in colchinine derivatives in organic solvents.22 Thereby, while 
COU-DCO and COU-DLC showed different peaks by HPLC analysis, using 
MS analysis the same molecular weight was observed for both dyads.  
Figure 6.2. Photodegradation of a) COU-PHA and b) COU-DCO at λmax ca. 350 
nm in an aerobic medium of MeOH/H2O (3/1) 
a) 
b) 





























Interestingly, the photolysis of COU-PHA was faster when the study 
was performed using a solution with higher proportion of water 
(MeOH/H2O 3/1, see Figure 6.2). Moreover, an increase of the release 
rate of COU and PHA was also detected during the first 15 min. These 
facts clearly evidence that water is needed for COU-PHA photolysis. By 
contrast, the rate of photolysis of COU-DCO did not change and the rate 
of COU released resulted to be lower than that observed in the 
photolysis of COU-PHA during its first minutes. These results are 
indicative that photolysis of COU-DCO is not water dependent and that 






Figure 6.3. Photodegradation of a) COU-DCO and b) COU-PHA using lamps at 
λmax ca. 420 nm in an aerobic medium of MeOH/H2O (3/1) 
Irradiations using lamps with emission at λmax ca. 420 nm were also 
used in these studies with the aim to inhibit the photoisomerization of 
the colchicine derivative of COU-DCO into COU-DLC. Nevertheless, 
unfortunately, as shown in Figure 6.3, same photolytic processes were 
detected. In this case, photoisomerization process occurs more slowly 
than with the use of UVA lamps. Interestingly, using the visible light, the 
a) 
b) 





























photorelease of COU was a clean process arising from COU-PHA and 
from COU-DLC because the percentage of COU released was 
approximately the same as those detected for the COU-PHA and COU-
DLC photodegraded. In this context, photorelease quantum yield (φPR) 
for COU-PHA and COU-DCO was determined using 
benzophenone/benzhydrol method (Table 6.1). 
Table 6.1. Photophysical and photochemical properties of DCO and the 
coumarin derivatives COU, COU-DCO and COU-PHA using a methanol/water 
(9/1) mixture. 
 DCO COU COU-DCO COU-PHA 
φF < 0.1x 10-3 0.57 0.09 0.53 
λF (max, nm) 442 447 458 456 
τ F (ns) < 1 4.1 1.81 4.0 
ES (kJ/mol) 296 298 291 295 
φ PR --- --- >0.0001 0.005 






























Figure 6.4. Emission of COU, COU-DCO and COU-PHA in methanol/water (9/1) 
mixture at room temperature 
6.2.2.1. Emission Properties of COU-DCO and COU-PHA 
To determine the photophysical properties of the singlet excited 
state of COU-DCO and COU-PHA steady state and time resolved 
emission measurements were performed at room temperature with 
these compounds dissolved in a methanol/water (9/1) mixture. 
Moreover, compounds COU and DCO were also studied under the same 
conditions as reference compounds. PHA was not included in this study 
because this compound does not absorb light at the excitation 
wavelengths of the photolysis performed. 
Fluorescence of COU-PHA shows an emission maximum at 456 nm 
and a fluorescence quantum yield (φF) of 0.53, which are properties 






Figure 6.4 and Table 6.1). However, in the case of COU-DCO, although 
its emission maximum is also similar to the observed for COU and COU-
PHA, its φF resulted to be considerably lower. In this context, DCO 
fluorescence was even lower. However, very small differences between 
the singlet excited state energies of COU, COU-PHA, COU-DCO and DCO 
were obtained when their values were determined from their emission 
and excitation spectra (Table 6.1). Interestingly, time resolved emission 
studies displayed a fluorescence lifetime (τ F) for COU quite similar to 
COU-PHA but these τ F are longer than those determined for COU-DCO 
and DCO (see Table 6.1). These results suggest that a new efficient 







Figure 6.5. a) Transient absorption spectra of COU-PHA in MeOH/H2O 3/1 
registered at different times between laser excitation at 375 nm and 50 ps. b) 





































































  Figure 6.6. a) Transient absorption spectra of COU-PHA in MeOH/H2O 3/1 
registered at different times up to 2700 ps after laser excitation at 375 nm. b) 
The corresponding kinetics from the laser pulse to 1500 ps at different 
wavelengths. 
6.2.2.2. Femtosecond transient absorption spectroscopy of COU-DCO 
and COU-PHA 
Femtosecond transient absorption measurements were performed 
with COU, DCO, COU-DCO and COU-PHA with the aim to detect all the 
a) 
b) 









































































short transient species formed after excitation of the coumarin 
derivative chromophore of COU-DCO and COU-PHA. The study 
performed with COU and COU-PHA shows the same intermediates and 
with similar lifetimes. In Figures 6.5 and 6.6 are shown the different 
transient species detected from COU-PHA. Hence, generation of an 
intermediate was detected during the initial few hundred 
femtoseconds after the laser pulse for both compounds. These 
transient species show a strong positive band located at around 390 nm 
and a broad negative band in the 420–550 nm region where the 
minimum is situated ca. 430 nm. A fitting analysis of the kinetic curve 
at 390 nm revealed a monoexponential component with a lifetime of 
ca. 1.5 ps for COU-PHA (see Figure 6.5.) The rapid absorption changes 
at these wavelengths also displayed a shift in the emission maximum 
(negative band) from 430 nm to 440 nm, which implies the generation 
of a second intermediate. In this context, the fact that an analysis of the 
kinetic curve at 428 nm shows a monoexponential fitting with a lifetime 
of ca.9 ps and a large red shift of the negative band of transient 
absorption spectrum is produced 15.5 ps after the laser pulse, implies 
the existence of another intermediate state (see Figure 6.5 for COU-
PHA). The minimum of the negative band of this transient species is 
coincident with the fluorescence band maximum observed for COU-
PHA and COU in steady state emission studies. Besides, the lifetime 
determined for the third intermediate of COU-PHA and COU (ca. 4 ns) 
is similar to these determined by time resolved emission studies (see 
Table 6.1). Thereby, as described in the literature for other coumarin 






state with an intramolecular charge transfer (ICT) character was 
detected. This ICT state undergoes in few picoseconds a stabilization 
after the diffusional solvent relaxation. Finally, a twisting of 7-amino 
substituent of this intermediate produces the formation of a twisted 
intramolecular charge transfer (TICT) state, which shows a lifetime of 















Figure 6.7. a) Transient absorption spectra of COU-DCO in MeOH/H2O 3/1 registered 
at different times between the laser pulse excitation at 375 nm to 30 ps. Inset: 
Transient absorption spectra of COU-DCO in MeOH/H2O 3/1 registered after 50 ps b) 
The corresponding kinetics from the laser pulse to 1500 ps at different wavelengths. 
a) 
b) 






























































































  Transient absorption spectra obtained during the first 30 ps from 
COU-DCO solutions resulted to be very different than those obtained 
from COU and COU-PHA (see Figure 6.7 and compare with Figure 6.5). 
However, analysis of the traces obtained at 390 nm and 430 nm showed 
similar lifetimes (ca 1 ps at 390 nm and ca. 8 ps at 428 nm) than those 
detected for COU and COU-PHA.  In this context, a study using DCO was 
Figure 6.8. a) Transient absorption spectra of DCO in MeOH/H2O 3/1 
registered at different times after the laser pulse excitation at 375 nm b) The 
corresponding kinetics from the laser pulse to 80 ps at different wavelengths. 
a) 
b) 





























































performed to determine the possible generation of fast transient 
species arising from DCO (see Figure 6.8). Thus, a strong band with a 
maximum at 515 nm appears instantaneously within the pulse duration 
and disappears within ca. 2ps leaving a broad structureless band with a 
maximum at around 480 nm and 410 nm. The second transient species 
showed a lifetime of ca. 30 ps. This implies that the excitation at 375 
nm can populate an excited state that rapidly converts into a second 
one. Such a rapid process is consistent with a rearrangement of the 
structure and of the charges after Franck-Condon excitation. These 
intermediates can be assigned as described for similar transient species 
detected for colchicine, to the DCO singlet excited states S11 and its 
lowest S1.25. Thereby, the differences in the transient absorption 
spectra between COU-PHA and COU-DCO can be attributed to the short 
transient species generated from the direct excitation of the 
chromophore corresponding to DCO. In fact, the transient absorption 
spectra registered from COU-DCO after 50 ps of the laser pulse 
correspond to the same transient species than those detected from 
COU-PHA at the same times (see Figure 6.6a and inset Figure 6.7a). 
Interestingly, the last intermediate detected from COU-DCO excitation, 
its twisted intramolecular charge transfer (TICT) state, showed a 
lifetime of ca. 2 ns, which is similar to the COU-DCO emission lifetime 






6.2.2.3. Nanosecond laser flash photolysis experiments using COU-
DCO and COU-PHA 
Laser flash photolysis assays were performed with COU, COU-DCO 
and COU-PHA with the aim to detect their triplet excited states. Hence, 
Figure 6.9. a) Transient absorption spectra of COU-PHA in deaerated 
MeOH/H2O 3/1 medium registered at different times after the laser pulse 
excitation at 355 nm b) Kinetics obtained at 580 nm from COU, COU-DCO and 
COU-PHA in deaerated MeOH/H2O 3/1 media. 
a) 
b) 















































the studies were performed under anaerobic conditions. In the case of 
COU and COU-PHA, both compounds, in MeOH/H2O 3/1 solutions, 
display the same transient species after excitation at 355 nm. The 
detected intermediate, accordingly with the literature,26 was the triplet 
excited state of the coumarin chromophore (see Figure 6.9a). However, 
no signals were obtained performing the same experiments using COU-
DCO. In fact, as it can be observed in Figure 6.9b, decay traces at the 
absorption maximum of these type of coumarin derivatives triplet 
excited state (ca. 580 nm) were only detected using COU and COU-PHA. 
Thus, it seems that the triplet excited state of COU-DCO is not 
generated. 
Prodrug COU-DCO was synthesized by linking a photolabile 7-amino-
4-hydroymethylcoumarine chromophore (COU) to N-
deacetylcolchicine (DCO) , an antineoplastic agent,20 via carbamate 
formation (see Scheme 6.1 and Scheme 6.2). However, liberation of the 
drug was not detected when the prodrug was irradiated using UVA light 
and also visible light at λmax ca. 420 nm in a methanol/aqueous medium. 
This unexpected result would be produced due to some photophysical  
property of DCO because it is well known that this coumarin derivative 
is able to photorelease other drugs.4,27,28 Two processes could explain 
the photostability observed for COU-DCO. One could be the generation 
of an energy transfer process from the singlet excited estate of COU 
(1COU) to DCO with the subsequent fast deactivation of the 1DCO. In 
fact, the efficient ultrafast internal conversion of colchicine derivatives 






transfer process between the singlet excited estate of COU (1COU) and 
DCO followed by back electron transfer reaction. The possibility that  an 
initial electron transfer process between 1COU and DCO to generate 
their corresponding radicals (see Equations 6.1 and 6.2 respectively) 
could occur was initially analyzed determining Gibbs free energies 
(ΔGPET) of the redox processes by using the Rehm-Weller equation 6.3:30 
 
1COU  + DCO   →   COU.- + DCO.+    Eq. 6.1 
1COU  + DCO   →   COU.+ + DCO.-    Eq. 6.2 
ΔGet = Eox -Ered –ES     Eq. 6.3 
 
Scheme 6.3. Chemical structure of the protecting group COU, the caged 
compounds DCO and PHA, and their chromophoric analogues of them such as 










Table 6.2. Redox potential of COU1, COL and BZ 
 Ered (V)a Eox (V)a 
COU1b -2.20 1.09 
COLc -1.04 1.22 
BZ -3.42d 2.48e 
aPotentials in V vs SCE. bRef.31,cRef.32 ,dRef.33,e Ref.34. 
The redox potentials of COU1 and COL (see values in Table 6.2 and 
structures in Figure 6.10)3135and the Es determined for COU-DCO (see 
Table 6.1) were used to determine ΔGPET of the electron transfer 
processes between the singlet excited state of the coumarin 
chromophore and the colchicine derivative ground state. Thereby, as 
results indicated that this electron transfer could occur, compound 
COU-PHA was synthesized for this study in order to compare the 
photophysical and photochemical properties of both dyads. COU-PHA 
was chosen   for this study because the ΔGPET for an electron transfer 
process to occur between COU and a phenyl derivative is theoretically 







Scheme 6.4. Main processes involved in the photodegradation of COU-PHA 
and COU-DCO. 
Thus, considering all the results obtained in this study, the main 
processes involved in the photodegradation of COU-PHA and COU-DCO 
are summarized in Scheme 6.4. After the analysis of the redox potential 
commented above, the results of the irradiations performed with COU-
DCO and COU-PHA have been proposed as well as the analysis of all the 
data obtained in the photophysical studies performed with COU, PHA, 
DCO, COU-PHA and COU-DCO.  
Thereby, although two deactivation processes were initially proposed 
to justify the absence of DCO photorelease from COU-DCO, an efficient 
energy transfer process between the chromophores of COU-DCO can 
be discarded because the energy determined for 1COU and 1DCO from 






generally accepted that the rate constant for an energy transfer 
reaction is nearly diffusion-controlled only when the energy level of the 
donor is at least 8 kJ/mol above that of the acceptor.36 Thus, only an 
electron transfer can occur. This process explains why COU-DCO 
fluorescence lifetime and quantum yield are lower than those 
determined for COU alone or for COU-PHA (see Table 6.1) Interestingly, 
these findings can also be correlated with the absence of COU or DCO 
photorelease during the first minutes of the COU-DCO irradiations. 
Moreover, it was observed that the intensity of the fluorescence of a 
solution of COU-DCO irradiated 15 min at λmax ca. 350 nm in an aerobic 
medium of MeOH/H2O (9/1, see Figure 6.1) increased along with the 
emission lifetime (data not showed). These results clearly indicate that 
when COU-DCO is phototransformed in COU-DLC, fluorescence 
quantum yield and emission lifetime of COU linked to DLC is similar to 
that determined for COU-PHA. In fact, both dyads seem to 
photorelease COU with similar efficiency (Figure 6.1-3). The effect of 
the water in the photorelease process of COU was clearly evidenced 
when with different amounts of water were used in the solution 
mixture (Figure 6.1 -2). Femtosecond studies have shown that the 
electron transfer process occurs from the twisted intramolecular 
charge transfer (TICT) singlet excited state of the COU chromophore 
because the other intermediates generated after excitation of all 
coumarin derivatives showed similar behaviour. The existence of this 
electron transfer process also explains why the triplet excited state of 







Photophysical and photochemical properties of COU are modified 
when the linked chromophore is able to generate an electron transfer 
process with the excited state of the coumarin chromophore. This study 
has clearly evidenced this fact using compounds COU, COU-DCO and 
COU-PHA. Moreover, the intermediated responsible of this type of 
electron transfer process has been established. It is also noteworthy 
that an initial analysis of redox properties and energies of the excited 
states of the compound to link are key points to prepare phototrigger-
controlled drug-release nanosystems. 
6.4. Experimental section 
6.4.1. Materials 
Selenium dioxide, ethyl bromoacetate, 4-(dimethylamino)pyridine, 
NaI, diisopropylethylamine, ethyl bromoacetate, di-tert-butyl 
decarbonate, 4-(dimethylamino)pyridine, triethylamine, trifluoroacetic 
acid, N,N'-carbonyldiimidazole and sodium methoxide solution (25 wt. 
% in methanol) were commercial products obtained from Sigma-Aldrich 
Chemical Company. 7-Amino-4-methylcoumarin was commercial 
product from Fluorochem. Colchicine and L-Phenylalanine tert-butyl 
ester hydrochloride were commercial products from Carbosynth. 
Sodium phosphate buffer (PB) was prepared from reagent-grade 
product from Sigma Aldrich using milli-Q water. One tablet dissolved in 
200 mL of deionized water yields 0.01 M phosphate buffer, pH 7.4, at 







6.4.2. Synthesis of COU, COU-DCO and COU-PHA 
7-[bis(ethoxycarbonylmethyl)lamino]-4-methylcoumarin. It was 
synthesized using the methodology described in the literature.37 7-
Amino-4-methylcoumarin (34.25 mmol, 6 g), NaI (34.25 mmol, 5.14 g), 
diisipropylethylamine (172.61 mmol, 30 mL), and ethyl bromoacetate 
(0.35 mol, 39 mL) in 165 mL of dry CH3CN were refluxed for 4 days 
under nitrogen atmosphere. The mixture was cooled to room 
temperature, filtered and the solvent was removed under reduced 
pressure. The residue was dissolved in EtOAc, washed with water and 
brine, dried over MgSO4, and concentrated under vacuum. The 
resulting oil was purified by silica-gel column chromatography (EtOAc/ 
Cyclohexane 1:1) to yield 1 (7.1 g, 20.55 mmol, 60%).  
1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 8.8 Hz, 1H), 6.55 (dd, J = 8.8, 
2.6 Hz, 1H), 6.47 (d, J = 2.6 Hz, 1H), 6.03 (d, J = 1.1 Hz, 1H), 4.20 (q, J = 
7.0 Hz, 4H), 4.10 (s, 4H), 2.34 (d, J = 1.1 Hz, 3H), 1.28 (q, J = 7.0 Hz, 6H).  
MH+ calculated for 7-[bis(ethoxycarbonylmethyl)lamino]-4-
methylcoumarin (C18H22NO6): 348.1448, found: 348.1455 
7-[bis(ethoxycarbonylmethyl)lamino]-4-(hydroxymethyl)coumarin 
(COU). To a solution of 138 mL p-xylene selenium dioxide (19.81 mmol, 
2.21 g) and 7-[bis(ethoxycarbonylmethyl)lamino]-4-methylcoumarin 
(13.36 mmol, 5 g) were added. The mixture was refluxed with vigorous 
stirring under a nitrogen atmosphere during 24 h. Afterwards it was 
filtered and concentrated under reduced pressure. The dark brown 






borohydride (6.76 mmol, 252.67 mg) was added. This mixture was 
stirred for 1 h at room temperature. Thereafter, the suspension was 
hydrolyzed adding HCl 1 M (10.5 mL). The solution was partially 
concentrated under reduced pressure to remove EtOH. Then, the 
aqueous mixture was extracted with EtOAc. The organic phase was 
washed H2O and brine, dried over MgSO4, and concentrated under 
vacuum. The resulting oil was purified by silica-gel column 
chromatography (EtOAc/Cyclohexane 1:1) to yield COU (2.66 g, 7.3 
mmol, 55 %). 
 1H NMR (300 MHz, CDCl3) δ 7.23 (d, J = 8.7 Hz, 1H), 6.47 (dd, J = 8.7, 
2.6 Hz, 1H), 6.43 (d, J = 2.6 Hz 1H), 6.28 (s, 1H), 4.68 (s, 2H), 4.25 (q, J = 
7.7 Hz, 4H), 4.10 (s, 4H), 1.27 (t, J = 7.4 Hz, 6H). MH+ calculated for COU 
(C18H22NO7): 364.1397, found: 364.1405. 
N-deacetylcolchicine (DCO). It was synthesized using the methodology 
described in the literature.38,39 Colchicine (8 g, 20.03 mmol) was 
dissolved in 81 mL of acetonitrile. To this were added 4-
(dimethylamino) pyridine (2.45 g, 20.03 mmol), triethylamine (5.44 mL, 
36.17 mmol), and di-tert-butyl dicarbonate (10.54 g, 48.28 mmol). The 
reaction flask was attached to a reflux condenser and heated at 100 °C. 
After 1 h additional di-tert-butyl dicarbonate (9.6 g, 43.9 mmol) was 
added. The reaction was quenched by the addition of 300 mL of CH2Cl2 
and was washed with 3 × 200 mL of saturated aqueous citric acid. The 
combined aqueous layers were back extracted with 30 mL of CH2Cl2, 
and the organic layers combined. The organic layer was washed with 






solid. The crude sample was carried on through the next step. The crude 
N-Boc-colchicine was dissolved in 115 mL of anhydrous methanol. To 
this was added sodium methoxide in methanol (26 mL 25% w/v) at 4°C. 
The solution was stirred at room temperature and monitored via thin 
layer. After 50 min the solution was transferred to 105 mL brine and 
extracted with 3 × 200 mL of diethyl ether. The product was dried over 
MgSO4, filtered, and concentrated to a crude solid. The crude sample 
was carried through the next reaction. N-Boc-deacetylcolchicine was 
dissolved in CH2Cl2 (115 mL) after which TFA (26 mL) was added. The 
reaction mixture was stirred for 2 h after which a saturated sodium 
carbonate solution (pH ca. 10) was carefully added to quench the 
reaction. This was extracted twice with CH2Cl2 and once with EtOAc. 
After pooling the organic fractions, drying over MgSO4 and 
concentration in vacuo, a thick brown oil was obtained. After silica-gel 
column chromatography with CH2Cl2/MeOH/Et3N (90:10:0.1) and 
concentration, DCO was obtained as a slightly yellow solid (3.8 g, 54%). 
MH+ calculated for DCO (C20H23NO5): 357.1516, found: 358.1658. 
1H NMR (300 MHz, CDCl3) δ 7.69 (s, 1H), 7.18 (s, 1H), 6.78 (d, J = 6.6 
Hz, 1H), 6.52 (d, J = 4.4 Hz, 1H), 3.97 (s, 1H), 3.91 (s, 1H), 3.74 – 3.68 
(m, 1H), 3.66 – 3.63 (m, 1H), 2.51 – 2.24 (m, 1H). 
COU-DCO. COU (1.062 g, 2.9 mmol) was added to a suspension of 
N,N'-carbonyldiimidazole (542.58 mg, 3.35 mmol) in anhydrous 
dichloromethane (78 mL). The mixture was refluxed in the dark and 
under nitrogen. After 4 h, a small sample was taken for analysis. The 






chromatography. The reaction mixture was cooled to room 
temperature, then 4-dimethylaminopyridine (171.04 mg, 1.4 mmol), 
DCO (1 g, 2.8 mmol) and dichloromethane (62 mL) were added. The 
resulting solution was heated to reflux for 4 h, then overnight at room 
temperature. After concentration under reduced pressure, the crude 
residue was purified by silica-gel column chromatography 
(EtOAc/MeOH 93:7) to yield COU-DCO as a yellow powder (700 mg, 34 
%). MH+ calculated for COU-DCO (C39H43N2O13): 747.2765, found: 
747.2765. 
1H NMR (300 MHz, CDCl3) δ 7.62 (s, 1H), 7.29 (d, J = 11.0 Hz, 1H), 
7.23 (d, J = 8.8 Hz, 1H), 6.85 (d, J = 11.0 Hz, 1H), 6.56 (s, 1H), 6.49 (dd, J 
= 8.9, 2.5 Hz, 1H), 6.45 (d, J = 2.5 Hz, 1H), 6.41 (d, J = 7.2 Hz, 1H), 5.30 
(d, J = 15.5 Hz, 1H), 4.86 (d, J = 15.5 Hz, 1H), 4.50 – 4.39 (m, J = 12.3, 5.9 
Hz, 1H), 4.22 (q, J = 7.1 Hz, 4H), 4.15 (s, J = 7.5 Hz ,4H), 4.00 (s, 3H), 3.91 
(d, J = 4.6 Hz, 6H), 3.53 (s, J = 19.3 Hz, 3H), 2.60 – 2.51 (m, 1H), 2.44 – 
2.28 (m, 2H), 1.98 – 1.84 (m, 1H), 1.66 (s, 1H), 1.28 (t, J = 7.1 Hz, 8H). 
13C NMR (75 MHz, CDCl3) δ 179.63 (s), 169.76 (s), 164.28 (s), 161.44 
(s), 155.60 (s), 154.68 (s), 153.67 (s), 151.23 (s), 151.07 (s, J = 12.4 Hz), 
150.97 (s), 149.94 (s), 141.76 (s), 136.21 (s), 135.42 (s), 134.31 (s), 
131.40 (s), 125.58 (s), 124.63 (s), 112.63 (s), 109.47 (s), 108.49 (s, J = 
25.6 Hz), 108.15 (s), 107.52 (s), 99.62 (s), 61.73 (s, J = 9.2 Hz), 61.50 (s), 
61.29 (s), 56.48 (s, J = 19.5 Hz), 56.23 (s), 54.29 (s), 53.49 (s), 37.21 (s), 
30.03 (s), 14.32 (s). 
COU-PHA. COU (200 g, 0.55 mmol) was added to a suspension of 






dichloromethane (14 mL). The mixture was refluxed in the dark and 
under nitrogen. After 4 h, a small sample was taken for analysis. The 
formation of the carbamate intermediate was confirmed by thin layer 
chromatography. The reaction mixture was cooled to room 
temperature, then 4-dimethylaminopyridine (30.5 mg, 0.25 mmol), L-
Phenylalanine tert-butyl ester hydrochloride (PHA, 178.7 mg, 0.5 
mmol) and dichloromethane (12 mL) were added. The resulting 
solution was heated to reflux for 4 h, then overnight at room 
temperature. After concentration under reduced pressure, the crude 
residue was purified by silica-gel column chromatography 
(EtOAc/Cyclohexane 2:1) to yield COU-PHA as a yellow powder (260 
mg, 42 %). MH+ calculated for COU-PHA(C32H39N2O10): 610.25, found: 
611.2585. 
1H NMR (300 MHz, CDCl3) δ 7.35 – 7.28 (m, 3H), 7.24 (s, 1H), 7.18 
(d, J = 1.5 Hz, 1H), 7.15 (s, 1H), 6.53 (dd, J = 8.8, 2.5 Hz, 1H), 6.49 (d, J = 
2.5 Hz, 1H), 6.19 (s, 1H), 5.38 (d, J = 8.0 Hz, 1H), 5.20 (d, J = 12.0 Hz, 2H), 
4.53 (dd, J = 14.0, 6.1 Hz, 1H), 4.24 (q, J = 7.1 Hz, 5H), 4.17 (s, 4H), 3.10 
(dd, J = 5.8, 2.1 Hz, 2H), 1.59 (s, 2H), 1.42 (s, 11H), 1.29 (q, J = 13.6, 6.4 
Hz, 12H). 
13C NMR (75 MHz, CDCl3) δ 170.11 (s), 169.44 (s), 161.06 (s), 155.39 
(s), 154.48 (s), 150.78 (s), 149.57 (s), 135.64 (s), 129.26 (s), 128.32 (s), 
126.92 (s), 124.40 (s), 109.09 (s), 108.26 (s), 108.16 (s, J = 7.6 Hz), 99.37 
(s), 82.39 (s), 61.62 (s), 61.41 (s, J = 16.3 Hz), 55.15 (s), 53.20 (s), 38.14 






6.4.3. Photolysis studies with CUO-DCO and COU-PHA 
Irradiations were performed in a Luzchem photoreactor (model LZC-
4V) equipped with eight lamps emitting in the 310-390 nm range 
(Gaussian distribution), with a maximum at 350 nm and other ones 
emitting in the 390-430 nm range (Gaussian distribution), with a 
maximum at 420 nm. All irradiations were performed under aerated 
medium at 10-4 M concentrations of each compound excluding the 
study for determining the photo-release quantum yield of COU-DCO 
and COU-PHA, which was performed under aerobic conditions using a 
solution of MeOH/10% H2O at the absorbance of 1. As actinometer was 
used the photoreaction of benzophenone (absorbance of 1 at 350 
nm)/benzhydrol (0.1 M) using φ = 0.68.40 All irradiations were done at 
room temperature using 1 cm pathway quartz cells with 4 mL capacity. 
The samples were irradiated during 30 min taking aliquots after 5, 10, 
20, 30, minutes of irradiation. Afterwards, COU-DCO and COU-PHA 
samples were monitored by HPLC on an analytical C18 column (25 x 0.4 
cm, mean particle size 5 μm) with flow rate of 0.7 mL/min, and a 
mixture of acetonitrile/water/trifluoroacetic acid 50/49.9/0.1 was used 
as eluent. In the case of the benzophenone samples, they were 
analyzed by UV-Vis spectroscopy determining the decrease of the 
absorbance at 360 nm.  
6.4.4. Laser flash photolysis experiments 
A pulsed Nd:YAG laser was used for the excitation at 355 nm. The 






The laser was a Lotis TII and the home-made detection system 
consisted of the pulsed laser, the Xe lamp, a monochromator and a 
photomultiplier made up of a tube, housing and power supply. The 
output signal from the oscilloscope was transferred to a personal 
computer. The studies were performed with 3 x 10-5 M COU and COU-
DCO and COU-PHA in methanol-buffered solutions of 1 mM PB (3/1). 
The experiments were registered under aerobic and anaerobic 
conditions. 
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Chapter 7: Developing biocompatible 
upconversion nanosystems for 
photocontrolled drug delivery using 










Cancer nanotherapeutics are rapidly progressing and are being 
implemented to solve the major limitations of conventional drug 
delivery systems such as toxic side effects, nonspecific biodistribution 
and targeting, lack of water solubility or poor oral bioavailability. The 
fast growth of novel nanomaterials has produced the development of 
nanocarrier systems, including liposomes, proteins, polymeric 
nanoparticles, dendrimers, silica and iron oxide nanoparticles and my 
other types, for targeted drug delivery.1 In this context, phototrigger-
controlled drug-release nanosystems have also been developed as 
promising tools for controlled-release drug delivery in tumor therapy. 
1–4 In general, this type of nanomaterials are composed of a 
biocompatible nanocarrier with the drug caged and a phototrigger 
(usually, coumarin or 2-nitrobenzyl derivatives), which can be 
manipulated by ultraviolet (UV) light to obtain the desired drug-release 
patterns.2–4 Nevertheless, this light has low penetration depth in living 
tissues, which is a limiting factor for applications in early diagnosis and 
cancer therapy.  
Other electromagnetic radiation such as near infrared (NIR) light can 
achieve high penetration in the body, however it cannot be directly 
used in phototrigger-controlled drug–release because most of the 
photoreactions require high energy UV or visible (Vis) light to occur. 
Fascinatingly, lanthanide-doped upconversion nanoparticles (UCNP) 
have the capability of converting NIR light into UV and Vis emissions in 






scaffolds of core-shell materials.5 These properties confer UCNP a 
significant potential for biomedical applications.6–9In the past few years, 
a widely applied approach to preparing phototrigger-controlled drug-
release nanosystems for NIR-triggered anticancer drug delivery is the 
combination of UCNP cores with different types of shells such as 
hydrogels, block copolymer micelles, and mesoporous silica 
nanoparticles, where phototriggers bearing excitable chromophores in 
the UV-Vis range and drugs are loaded.10–15 The underlying 
fundamental principle is that controlled NIR light excitation of UCNP 
generates UV-Vis emission inside the nanosystem which is absorbed by 
phototrigger to bring about the photochemical reaction responsible for 
drug release.  
Two strategies have been employed to design the nanosystems: a) 
a drug is caged into an external shell formed by long-chain organic 
molecules with ionic properties or by different types of polymers which 
contain a phototrigger within their backbone. Exposure to UV or visible 
light causes chain scission and drug release. 11–14 b) A prodrug formed 
by a phototrigger covalently attached to the drug is loaded inside 
hollow inert cavities of a silica shell by physical adsorption. In this case, 
excitation of the phototrigger produce photolysis of the prodrug with 
consequent drug release.15 Both types of nanosystems have shown to 
be effective for drug delivery, however, the biocompatibility of silica 
nanoparticles and some polymers have recently been questioned.16–19 
With this background, we are interested in developing a new 






biocompatible. Human serum albumin (HSA) was selected as the shell 
of the new nanomaterial because this protein is an ideal platform for 
effective delivery of drugs, mostly attributed to its unique features of 
low toxicity, minimized inflammatory stimulation and 
biodegradability.20,21 Moreover, HSA nanoparticles are excellent drug 
carrier systems and offer the possibility of surface modification with 
ligands as folic acid for the selective targeting of drugs into tumor 
cells.22 The most convenient way to connect an organic compound such 
as a prodrug to albumin is probably introducing the molecule into the 
cavities of the albumin because, at the same time that the association 
is produced, the protein acts as protecting prodrug from enzymatic 
processes. For this purpose, it is mandatory that the prodrug, a 
phototrigger chromophore covalently linked to a pharmaceutical 
compound, has high binding affinity to HSA. Besides, at the same time, 
it is convenient that the drug has the inverse property to favor its 
release to the medium when the prodrug complexed to HSA is 
photoactivated. 
7.2.  Results and discussion 
Looking for excellent phototriggers with high binding affinity for HSA 
in the literature it was found that most coumarin derivatives show high 
association constants to HSA (Ka > 104 M-1).23 In fact, warfarin, a 
compound of this family, is usually employed as reference compound 
for albumin binding Site I and has a Ka of 5.4 x 105 M-1.24 In this context, 








Scheme 7.1. A) Synthesis of prodrug (COU-CHB). B) Synthesis of the 
nanostructure UCNP(NaYF4 : Yb/Er)@PAA@HSA containing an UCNP core and 
a shell of HSA covalently linked to PAA). C) Photoactivatable drug-release 











Scheme 1. A) Synthesis of prodrug (COU-CHB). B) Synthesis of the nanostructure UCNP(NaYF4 : Yb/Er)@PAA@HSA containing an UCNP core and a shell of 









The pharmacologically active agent chosen to complete the prodrug 
was chlorambucil (CHB) because this anticancer compound has a very 
low binding affinity to HSA (Ka < 103 M-1),25 Moreover, the generation of 
a photolabile covalent bond between the carboxylic group of CHB and 
the 4-hydroxymethyl substituent of COU is feasible. Thereby, synthesis 
of the conjugated coumarin chlorambucil prodrug (COU-CHB, Scheme 
7.1A) was performed by esterification of 7-
[bis(ethoxycarbonylmethyl)lamino]-4-(hydroxymethyl)coumarin (COU) 
with CHB using N,N´-dicyclohexylcarbodiimide coupling reagent to yield 
60 %. Its structure was unambiguously assigned using NMR 
spectroscopy and UPLC-HRMS (details of the data and the synthetic 
route to obtain COU are described in the experimental section below). 
Next, irradiations of the prodrug in methanol/water (1/1) solutions 
were performed with white lamps emitting in the 380-460 nm range to 
confirm that this compound can be used as a photoactivatable prodrug 
b) a) 
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Figure 7.1. a) Absorption spectrum of COU-CHB prodrug in methanol/H2O 
(3/1) and emission spectrum of the peak at ca. 410 nm of UCNP (NaYF4: Yb/Er 
18/2) using 980 nm excitation wavelength. b) Emission spectra of COU and 






in nanoystems containing UCNP with UV-Vis emissions (see the overlap 
between the absorption spectrum of prodrug and emission spectrum 
of UCNP in Figure 7.1a). The result proved that photolysis of COU-CHB 
gave rise to the release of CHB and COU (see Scheme 7.2). Experimental 
details of this reaction are provided in the experimental section. 
 
Scheme 7.2. Main pathways of COU-CHB prodrug photolysis. 
The photochemical processes involving the heterolytic bond 
cleavage of COU-CHB were evaluated performing steady state and time 
resolved emission measurements as well as laser flash photolysis 
experiments using COU-CHB and COU in buffered H2O/methanol (1/1) 
solutions. Notably, the COU fluorescence quantum yield (φF) decreases 
when it is attached to CHB (see green fluorescence pathway (Fl) in 
Scheme 7.2). Thus, a φF of ca. 0.57 versus 0.09 were determined for 






This result and the shortening of the prodrug emission lifetime (τF) as 
compared with that of COU (τF ca. 3.3 ns and 4.8 ns respectively), 
suggest a prodrug photolysis arising from the coumarin singlet excited 
state (1(COU)*, see the blue pathway D in Scheme 7.2) as previously 
reported in the literature for closely related compounds.26 
Further support for the photolytic pathway D was found performing 
laser flash photolysis experiments with COU and COU-CHB because the 
characteristic absorption spectrum of coumarin chromophore triplet 
excited state (λmax ca. 620 nm)27was only detected using COU (see 
Figure 7.2; more evidences for this triplet state assignment in the 
experimental section). The detected traces of the coumarin triplet 
excited state were very noisy because all 7-aminocoumarins have poor 
intersystem crossing (ISC) efficiencies.28 Accordingly, the photolytic 
pathway D, which only occurs from COU-CHB, besides decreasing 
 















































Figure 7.2. Transient absorption spectrum of a methanol/ 1 mM PB (1/1) 
solution of 3 x 10-5 M COU under anaerobic conditions (N2) 1 μs after the laser 







fluorescence (Fl) pathway significantly, produces the almost complete 
suppression of the ISC process (Scheme 7.2). It should be mentioned 
that the photolysis of this type of coumarin prodrugs needs water to 
release the drug.26 
The nanocarrier HSA-coated theranostic UCNP (UCNP@PAA@HSA), 
was synthesized using a methodology described in the literature for a 
similar UCNP using bovine serum albumin. 29 All the steps to obtain the 
nanosystem UCNP (NaYF4: Yb/Er) @PAA@HSA are shown in Scheme 
7.1B (experimental and some characterization details are provided in 
experimental section and in Figure 7.7). Summarizing, the initial NaYF4: 
Yb/Er nanoparticles were synthesized by Ostwald Ripening method (see 
 














  a) UCNP
  b) UCNP@PAA
  c) UCNP@PAA@HSA
d)
Figure 7.3. TEM of a) UCNP (NaYF4: Yb/Er) b) UCNP@PAA, c) UCNP@PAA@HSA, 






structure in Figure 7.3a). The UCNPs showed a size of ca. 100 nm and 
their emission spectra displayed peaks at λmax ca. 408, 545 and 660 nm, 
which is typical when the percentage of lanthanides are 18 % Ytterbium 
and 2 % of Erbium. An exchange between the non-polar shell of oleic 
acid of the initial UCNP and polyacrylic acid (PAA) was done to give 
biocompatibility to the UCNP following literature protocol.29 Thus, an 
additional shell 7 ± 3 nm in thickness was observed, pointing to the 
presence of a PAA layer around each particle (see Figure 7.3b). 
Moreover, these particles showed an UV absorption attributable to the 
PAA (Figure 7.3d). 
The HSA shell was achieved by amidation of PAA carboxylic acids 
with primary amino groups present in the protein chain. The specific 
tendency to accumulate HSA on the surface of NaYF4: Yb/Er @PAA can 
be observed comparing Figures 7.3b and 7.3c. The presence of the 
protein on NaYF4: Yb/Er @PAA nanoparticle was also confirmed using 
UV-Vis spectrometry (Figure 7.3d). Thus, the UCNP@PAA@HSA 
nanosystem showed a new peak at ca. 280 nm, which is attributable to 
the HSA absorption. In this context, the emission properties of 






observed for the primary UCNP (see their emission spectra in Figure 7.6 
of the experimental section). 
The next step to prepare the final nanosystem (UCNP@PAA@HSA--
-COU-CHB) was to determine the association constant (Ka) between 
albumin and the COU-CHB prodrug. Hence, this data was determined 
using the emission quenching of the tryptophan unit (Trp) of HSA by the 
presence of COU-CHB (experimental details are included in the 
experimental section). Interestingly, a Ka value of ca. 1.5 105 M-1 was 
obtained (see Figure 7.7. for more details). This value predicts an 
efficient binding between the prodrug and the HSA of our nanosystem. 
Thereby, taking into account this Ka, COU-CHB was loaded into the 
albumin sites of UPNP@PAA@HSA in more than 95 % using 2 x 10-5 M 
buffered aqueous mixtures of the albumin linked to the nanosystem 























Figure 7.4. Absorption spectra of UCNP@PAA@HSA and COU-CHB loaded to 






Details of the COU-CHB loading are included in experimental section. 
Afterwards, the UPNP@PAA@HSA---COU-CHB nanosystem was tested 
in aqueous media using a 980 nm NIR laser 1 W/cm2 continuous-wave. 







Scheme 7.3. Chlorambucil release from UPNP@PAA@HSA---COU-CHB 
nanosystem photoinduced by NIR light.  
 

















Figure 7.5. The time course of CHB release from UCNP@PAA@HSA---COU-CHB 
nanosystem using NIR light at 980 nm (1 W cm-2) and dark conditions. ‘‘ON’’ 







Near infrared upconversion excitation triggers UVA-Vis emission 
from the nanoparticles which in turn is converted to COU excitation in 
the prodrug. The subsequent coumarin singlet excited state generation 
produces the CHB releasing. Figure 7.5 shows the partial progress for 
the release of CHB from UPNP@PAA@HSA---COU-CHB nanosystem 
using NIR light at 980 nm (1 W cm-2) and under dark conditions (more 
details are given in experimental section). Interestingly, delivery of COU 
or another coumarin derivative was not detected. The lack of 
complexation between COU and HSA determined using a similar 
emission quenching study than that performed for COU-CHB indicates 
that the Ka of COU---HSA must be lower than 104 M-1. A nucleophilic 
attack of some free amino group of the albumin to COU would be in 
accordance to the COU-CHB fragmentation results (see mechanism in 
Scheme 7.3). Thereby, a clean drug release is produced in the NIR 
triggered process.  
7.3. Conclusions 
In summary, we have developed an upconversion-based 
phototriggered drug-release device using HSA as biocompatible shell. 
The anticancer drug chlorambucil linked to an hydroxycoumarin 
derivative phototrigger was loaded into nanocages of 
UCNP@PAA@HSA through the generation of albumin-prodrug 
complexes. Irradiation of this nanosystem at 980 nm produces the 
controlled cleavage of the coumarin phototrigger releasing only the 
drug into the bulk solution. The binding affinity of chemicals to HSA is a 






delivery systems with very high biocompatibility. This approach could 
be extended to load other anticancer drugs such as doxorubicin in 
UCNP@PAA@HSA and more importantly, it offers the possibility to 
rescue colchicine and other antineoplastic chemicals that were 
discarded for cancer treatments due to their high toxicities. 
7.4. Experimental section 
7.4.1. Materials 
Selenium dioxide, ethyl bromoacetate, chlorambucil, 4-
(dimethylamino)pyridine, Yttrium (III) chloride (YCl3), Ytterbium (III) 
chloride (YbCl3), Erbium (III) chloride (ErCl3), oleic acid (OA), 1-
octadecene (ODE), ammonium fluoride (NH4F), sodium hydroxide 
(NaOH), polyacrylic acid (PAA) and human serum albumin fatty acid free 
(HSA) were commercial products obtained from Sigma-Aldrich 
Chemical Company. 7-Amino-4-methylcoumarin was a commercial 
product from Fluorochem. Sodium phosphate buffer (PB) and sodium 
bicarbonate buffer were prepared from reagent-grade products using 
milli-Q water; the pH of the solutions was measured through a glass 
electrode and adjusted with NaOH to pH ca. 7.4. Other chemicals were 
of reagent grade and used as received. 0.45 µm diameter PTFE filters 
were bought from Labbox. 







Ultraviolet spectra were recorded on a UV/Vis scanning 
spectrophotometer (Cary 50). Fluorescence emission spectra were 
recorded on a Photon Technology International (PTI) LPS-220B 
fluorimeter. Lifetimes were measured with a time resolved 
spectrometer (TimeMaster fluorescence lifetime spectrometer TM-
2/2003) from PTI by means of the stroboscopic technique, which is a 
variation of the boxcar technique. A hydrogen/nitrogen flashlamp (1.8 
ns pulse width) was used as excitation source. The kinetic traces were 
fitted with monoexponential decay functions. Measurements were 
made under aerated conditions at room temperature (25 °C) in 
cuvettes of 1 cm path length. The excitation wavelength used to 
register the fluorescence lifetimes was 450 nm. The fluorescence 
quantum yield of quinine bisulphate in 1 N H2SO4 (φF = 0.546) was used 
as standard. 
7.4.3. Experimental and results of laser flash photolysis experiments 
 A pulsed Nd:YAG laser was used for the excitation at 355 nm. The 
single pulses were 10 ns duration and the energy was from 10 to 1 
mJ/pulse. A pulsed xenon lamp was employed as detecting light source. 
The laser flash photolysis apparatus consisted of the pulsed laser, the 
Xe lamp, a monochromator and a photomultiplier made up of a tube, 
housing and power supply. The output signal from the oscilloscope was 






The studies were performed with 3 x 10-5 M COU and COU-CHB in 
buffered solutions of 1 mM PB/methanol (1/1). The experiments were 
registered under aerobic and anaerobic conditions. 
Additional results. Absorption spectrum obtained for COU under 
anaerobic conditions corresponds, in accordance to the literature,27 to 
the triplet excited state of the coumarin chromophore. A lifetime of 
28.7 μs was determined under our experimental conditions. Moreover, 
as expected for a triplet excited state species, the intermediate was 
efficiently quenched by the presence of oxygen. By contrast, COU-CHB 
did not show any signal using the same experimental conditions. 
7.4.4. Experimental for drug release studies  
The release of CHB from prodrug COU-CHB associated or not to the 
protein shell of UCNP@PAA@HSA was studied by HPLC. The equipment 
used was the Agilent 1100 series LC model with a quaternary pump 
G1311A and photodiode array detector G1315B and wavelength 
detection from 200 nm to 600 nm equipped with a Mediterranean Sea 
C18 (25 x 0.46 cm, particle size of 5µm). The mobile phase was 
acetonitrile/water/Trifluoroacetic acid 40/59.9/0.1 at a flow rate of 1.5 
mL/min flow.  
7.4.4.1. Procedure for prodrug COU-CHB 
A solution of 1mM PB/MeOH (1/1) containing 10-5 M of the prodrug 
was irradiated during 60 min in a photoreactor using four white lamps 






Gaussian distribution. Samples were taken at 30 and 60 min and 
analyzed by HPLC. 
7.4.4.2. Procedure for nanosystem UCNP@PAA@HSA···COU-CHB 
The solution containing the nanosystem (conditions in the above 
section) was irradiated in a quartz cuvette of 1 cm path length with an 
infrared laser RLTMDL-980 1-2000 mW (PSU-III-LED) at λmax = 980 nm ± 
5 nm and 1000 mW power during 240 min with continuous stirring. 
Dark samples and irradiated samples were taken at 0 min, 60, 120, 180 
and 240 min and were analyzed by HPLC after being centrifuged. 
7.4.5. Synthetic route and characterization of prodrug COU-CHB 
 
Scheme 7.1. Synthesis of prodrug COU-CHB from 7-Amino-4-methylcoumarin. 
7-[bis(ethoxycarbonylmethyl)lamino]-4-methylcoumarin (1). It was 
synthesized using the methodology described in the literature.30 7-
Amino-4-methylcoumarin (34.25 mmol, 6 g), NaI (34.25 mmol, 5.14 g), 
diisipropylethylamine (172.61 mmol, 30 mL), and ethyl bromoacetate 






under nitrogen atmosphere. The mixture was cooled to room 
temperature, filtered and the solvent was removed under reduced 
pressure. The residue was dissolved in EtOAc, washed with water and 
brine, dried over MgSO4, and concentrated under vacuum. The 
resulting oil was purified by silica-gel column chromatography (EtOAc/ 
Cyclohexane 1:1) to yield 1 (7.1 g, 20.55 mmol, 60%).  
1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 8.8 Hz, 1H), 6.55 (dd, J = 8.8, 
2.6 Hz, 1H), 6.47 (d, J = 2.6 Hz, 1H), 6.03 (d, J = 1.1 Hz, 1H), 4.20 (q, J = 
7.0 Hz, 4H), 4.10 (s, 4H), 2.34 (d, J = 1.1 Hz, 3H), 1.28 (q, J = 7.0 Hz, 6H).  
MH+ calculated for 1 (C18H22NO6): 348.1448, found: 348.1455. 
7-[bis(ethoxycarbonylmethyl)lamino]-4-(hydroxymethyl)coumarin 
(COU). Selenium dioxide (19.81 mmol, 2.21 g) and compound 1 (13.36 
mmol, 5 g) in 138 mL p-xylene were refluxed with vigorous stirring 
under a nitrogen atmosphere. After 24 h, the mixture was filtered and 
concentrated under reduced pressure. The dark brown residual oil was 
dissolved in ethanol (100 mL), then sodium borohydride (6.76 mmol, 
252.67 mg) was added, and the solution was stirred for 1 h at room 
temperature. Thereafter, the suspension was carefully hydrolyzed with 
1 M (6.7 mL), diluted with H2O, and partially concentrated under 
reduced pressure to remove EtOH. The resulting mixture was extracted 
with EtOAc. The organic phase was washed with H2O and brine, dried 
over MgSO4, and concentrated under vacuum. The resulting oil was 
purified by silica-gel column chromatography (EtOAc/Cyclohexane 1:1) 






 1H NMR (300 MHz, CDCl3) δ 7.23 (d, J = 8.7 Hz, 1H), 6.47 (dd, J = 8.7, 
2.6 Hz, 1H), 6.43 (d, J = 2.6 Hz 1H), 6.28 (s, 1H), 4.68 (s, 2H), 4.25 (q, J = 
7.7 Hz, 4H), 4.10 (s, 4H), 1.27 (t, J = 7.4 Hz, 6H). MH+ calculated for COU 
(C18H22NO7): 364.1397, found: 364.1405. 
COU-CHB. Under dark conditions, a mixture of COU (379 mg, 1.09 
mmol), chlorambucil (400 mg, 1.31 mmol), EDC (146 mg, 0.76 mmol), 
and DMAP (26.9 mg, 0.022 mmol) was dissolved in 135 mL anhydrous 
CH2Cl2 under nitrogen atmosphere. After stirring at room temperature 
for 4 h, the solvent was removed under vacuum. The obtained crude 
product was purified by preparative TLC (Cyclohexane: ethyl acetate = 
1.2: 0.8) to yield COU-CHL (424 mg, 0.65 mmol, 60 %). MH+ calculated 
for COU-CHB (C32H39N2O8Cl2): 649.2083, found: 649.2101. 
1H NMR (300 MHz, CDCl3) δ 7.33 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 8.8 
Hz, 1H), 6.62 (d, J = 8.7 Hz, 1H), 6.54 (dd, J = 8.9, 2.6 Hz, 1H), 6.49 (d, J 
= 2.6 Hz, 1H), 5.19 (d, J = 1.4 Hz, 1H), 4.30 – 4.11 (m, 5H), 3.73 – 3.56 
(m, 5H), 2.58 (t, J = 7.4 Hz, 1H), 2.44 (t, J = 7.5 Hz, 1H), 1.96 (p, J = 7.5 
Hz, 1H), 1.29 (t, J = 7.1 Hz, 4H).  
13C NMR (75 MHz, CDCl3) δ 172.71, 169.58, 161.23, 155.62, 151.06, 
149.28, 144.47, 130.13, 129.70, 124.57, 112.24, 109.33, 108.56 108.43, 
99.61, 61.62, 61.02, 53.59, 53.39, 40.56, 33.90, 33.33, 26.53, 14.21.   
7.4.6. Synthetic route and additional results for obtaining NaYF4: 
Yb/Er (18%, 2%) @PAA@HSA···COU-CHB nanosystem 






The salts YCl3·H2O (0.8 mmol), YbCl3·H2O (0.18 mmol) and ErCl3·H2O 
(0.02 mmol) were mixed with 12 mL of oleic acid (OA) and 15 mL of 
octadecene (ODE) in 100 mL 3 necked flask. The solution was heated to 
160 0C to form a homogeneous solution and then cooled down to room 
temperature under nitrogen flow. Afterwards, 10 mL methanol solution 
containing NH4F (4 mmol) and NaOH (2.5 mmol) was added, and the 
solution stirred for 30 minutes. Vacuum-nitrogen cycles were done to 
help methanol evaporation. Then, the solution was heated to 305 °C, 
maintained at this temperature for 2 hours under Ar atmosphere, and 
then cooled down to room temperature. The resultant nanocrystals 
were precipitated by the addition of ethanol, washed with ethanol-
water (1:1 v/v) three times, collected by centrifugation and finally 
resuspended in cyclohexane. Characterization of the nanoparticles was 
performed using the Transmission electron microscopy JEOL JEM—






 NaYF4: Yb (18%), Er (2%)
0 10 20 30 40 50 60 70 80 90
2 (degrees)  
Figure 7.6. XRD spectra of NaYF4: 18% Yb,2%Er and standard JCPDS PDF 
number 16-0334 
7.4.6.2. Surface modification of NaYF4: Yb/Er (18%, 2%) with 
polyacrylic acid (PAA)29 
To obtain hydrophilic nanoparticles, the prepared UCNP (50 mg) 
were dissolved in 2.5 mL of toluene. In a 100 mL three-necked flask, 
150 mg of polyacrylic acid (PAA) was dissolved in 15 mL of diethylene 
glycol (DEG) and heated to 110 °C to form homogeneous solution. A 
solution of toluene with nanoparticles was slowly added to the mixture 
and left 1 hour with vigorous stirring under nitrogen atmosphere. Then 
the solution was heated to 240 °C for 1.5 hours and afterwards, cooled 
down to room temperature. Nanoparticles were precipitated with 
ethanol, centrifugated at 4000 rpm for 1 hour, and then washed 3 times 
with ethanol/water (1:1) at 4000 rpm 1 hour each. Finally, NaYF4: Yb/Er 
(18%, 2%) @PAA were dispersed in deionized water and preserved at 4 






7.4.6.3. Functionalization of NaYF4: Yb/Er (18%, 2%)@PAA with 
Human Serum Albumin (HSA)29 
100 mg of fatty acid free HSA and 5 mg of N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride were 
dissolved in 5 mL aqueous solution of NaYF4: Yb/Er (18%, 2%)@PAA of 
2 mg/mL. After 2 hours of vigorous stirring, 5 mg of EDC were added. 
The reaction mixture was maintained at room temperature 6 hours. 
Nanoparticles were precipitated by centrifugation with water at 6000 
rpm for 1 hour. Finally, nanocrystals were dispersed in water and 
maintained at 4 °C. 
7.4.6.4. Preparation of nanosystem NaYF4: Yb/Er (18%, 2%) 
@PAA@HSA···COU-CHB 
To 3 mL of an aqueous solution of NaYF4: Yb/Er (18%, 
2%)@PAA@HSA (2 mg/mL of nanoparticles with a HSA concentration 
of ca. 2 x 10-5 M) 3 µL of 10-2 M prodrug COU-CHB in DMSO were added 
to load the prodrug int the nanoparticles. The mixture was kept under 
continuous stirring in the dark for 10 minutes. Afterwards, sample was 
centrifuged at 6000 rpm over 30 minutes and washed twice with 
distilled water. Finally, an UV-Vis spectrum of precipitated in water was 









7.4.6.5. Analysis of complexation between prodrug COU or COU-CHB 
and HSA 
The study was performed using free fatty acid HSA (10-4M) and 
different amounts of COU or prodrug COU-CHL. The sample was 
analyzed by UV-Vis spectrometry and fluorescence spectroscopy after 
5 min stirring. The association constants were determined using the 
Figure 7.6. a) EDS-TEM of UCNP. b) Histogram of distribution size of UCNP. c) 
Emission spectrum of UCNP, NaYF4: Yb/Er (18%, 2%)@PAA and NaYF4: Yb/Er 
(18%, 2%)@PAA@HSA at the excitation wavelength of 980 nm. d) 
Amplification of the emission band centered at 410 nm. e) Photography of 






HSA fluorescence band (λmax ≈ 344 nm) after excitation at 295 nm as 
described in the literature.32 The fluorescence quenching of this band 
was monitored adding increasing amounts of COU or prodrug COU-CHL 
(from 2 x 10-7 M to 2 x 10-6 M). Before analyzing the data, inner filter 
effect correction (IFE) was applied because both compounds absorb 
light at the excitation and emission wavelengths. The IFE correction was 
applied using Equation 7.1: 
Fcorr= Fobs x 10(Aex + Aem)/2                 Eq. 7.1 
Where Fcorr and Fobs are the corrected and the observed 
fluorescence respectively, and Aex and Aem are the absorbance values at 
the excitation and emission wavelengths, respectively.  
Thus, the corrected data were analyzed using the Equation 7.1 to 
determine the association constant (Ka) between albumin and COU or 
the prodrug.  
F0/F = 1 + Ksv·[Q]                  Eq. 7.2 
F0 and F are the fluorescence intensities in the absence and 
presence of the quencher respectively, [Q] is the quencher 
concentration and Ksv is the Stern-Volmer quenching constant, that is a 






Figure 7.7. a) Emission of HSA at different prodrug concentrations. b) Plot of 
(F0/F)-1 vs prodrug concentration to determine Ka. 
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8.1. General instrumentation 
8.1.1. Nuclear magnetic resonance (NMR)  
The one-dimensional (1H, 13C, DEPT-135) NMR spectra were 
measured by a 300 MHz Varian Bruker instrument, using DMSO-d6 and 
CDCl3 as solvents. The corresponding solvent signals were taken as 
reference (chemical shift of δ of ca 2.50 ppm and 7.26 ppm for 1H NMR 
and 39.52 and 77.16 ppm for 13C NMR, respectively). Coupling 
constants (J) are given in hertz (Hz). 
8.1.2. Chromatography 
8.1.2.1. Thin-layer liquid chromatography (TLC)  
Thin-layer liquid analysis were performed using SiO2 (silica gel F254) as 
the stationary phase. In the case of Liquid Chromatography silica gel 60, 
SDS, 230-400 mesh ASTM was used. 
8.1.2.2. High performance liquid chromatography 
All samples were analyzed on an Agilent 1100 Series HPLC set up 
equipped with a diode array detector covering a detection range from 
200 to 400 nm. Analysis were performed using a Mediterranean Sea 
C18 column (250 x 4.6 mm, 5 μm). In all cases the H2O mobile phase 
was acidified at a pH of ca. 3 and the flow rate set at 1,5 mL/min.  







Analysis were performed using an UPLC-MS/MS:  ACQUITY UPLC 
system (Waters Corp.) with a conditioned autosampler at 4 °C. The 
system uses an ACQUITY UPLC BEH C18 column (50 mm × 2.1 mm i.d., 
1.7 μm) maintained at 40 °C. The analysis was achieved with gradient 
elution using acetonitrile and water (containing 0.01% formic acid) as 
the mobile phase. The Waters ACQUITY™ XevoQToF Spectrometer 
(Waters Corp.) was connected to the UPLC system via an electrospray 
ionization (ESI) interface. The ESI source was operated in positive 
ionization mode with the capillary voltage at 3.0 kV. The temperature 
of the source and desolvation was set at 100 °C and 400 °C, 
respectively. The cone and desolvation gas flows were 100 L h−1 and 
800 L h−1, respectively. All data collected in Centroid mode were 
acquired using Masslynx™ software (Waters Corp.). Leucine-enkephalin 
was used as the lock mass generating an [M+H]+ ion (m/z 556.2771) at 
a concentration of 500 pg/mL and flow rate of 50 μL/min to ensure 
accuracy during the MS analysis. 
8.2. Photochemical instrumentation 
8.2.1. UV-VIS absorption spectroscopy  
All UV-Vis absorption spectra were registered with a simple beam 
Varian Cary 50 spectrophotometer, using quartz cells of 1cm optical 
path length. 






Time‐resolved fluorescence spectra were recorded on an EasyLife V 
(OBB) spectrofluorimeter. The apparatus was equipped with a diode 
LED (λexc = 340 nm) excitation source; the residual excitation signal was 
filtered in emission by using a cut‐off filter (50 % transmission at 380 
nm). 
8.2.3. Steady-state photolysis  
Irradiation of the samples was performed under anaerobic conditions 
in quartz cuvettes of 1 cm optical path length, quartz flasks o, using 
three a Luzchem photoreactor (model LZV-4V) with a variable number 
of lamps (maximum output at 350 nm or 420 nm). 
8.2.4. Laser flash photolysis spectroscopy (LFP)  
For the LFP a pulsed Nd: YAG SL404G-10 Spectron Laser Systems, 
was used at 355 nm (3rd harmonic) as the excitation wavelength, and 
the energy of the single pulses (ca 10 ns duration) was setted under 15 
mJ pulses. The apparatus consisted of the pulsed laser, a pulsed Lo255 
Oriel Xenon lamp, a 
77200 Oriel monochromator, an 70705 Oriel photomultiplier tube 
(PMT) housing, a 70705 PMT power supply and a TDS-640A Tektronix 
oscilloscope. The output signal from the oscilloscope was transferred 
to a personal computer and all experiments were performed in quartz 
cuvettes of 1 cm optical path. 






Transient absorption spectra were recorded using a compact 
regenerative amplifier LIBRA-HE Coherent, a tunable optical 
paramagnetic amplifier OPERA-SOLO Coherent and the transient 
absorption spectrometer ExciPro (CDP Systems). Thus, femtosecond 
laser pulses are produced by a commercial regenerative amplified laser 
system LIBRA Coherent including in its optical bench an oscillator 
VITESSE (To seed), a Nd-YLF laser Evolution (to pump the Ti-Za crystal), 
a regenerative amplifier itself and a stretcher/compressor which 
outputs 100 fs, 4 mJ pulses centred at 800 nm with a 1 kHz repetition 
rate. The beam is split into two parts:  one beam is used for white light 
generation (the probe beams) and the second beam is used to pump 
the tunable optical paramagnetic amplifier OPERA-SOLO Coherent 
(Light Conversion, TOPAS (UV-VIS)). The OPA provides the pump source 
with tuneable wavelengths in the range 245–2600 nm and a duration 
of 100 fs pulse. In the present case, the pump was set at 340 nm (ca. 5 
μJ pulses) and passed through a chopper prior to focusing onto the 
sample rotating cell (0.8 mm optical path length) placed into the 
transient absorption spectrometer ExciPro (CDP Systems). The white 
light used as probe was produced after part of the 800 nm light from 
the amplifier passed through a computer-controlled 8 ns variable 
optical delay line and impinged on a CaF2 rotating crystal. This white 
light was split in two identical portions to generate reference and probe 
beams that then were focused on the rotating cell containing the 
sample. The pump and the probe coincided in the interrogation of the 






this path to measure the probe and the reference pulses and to obtain 
the transient absorption decays and spectra.  
8.2.6. Phosphorescence emission measurements 
The phosphorescence spectra were recorded using a 
spectrophosphorimeter Photon Technology International (PTI, 
TimeMater TM/2003) equipped with a pulsed Xenon lamp. Compounds 
were dissolved in ethanol, adjusting their absorbance at ca. 0.8 at the 
excitation wavelength, with cuvettes of 1cm optical pathway. 
Measurements were carried out in a quartz tube (0.5 mm diameter) at 
77 K.  
Singlet-oxygen measurements were performed registering 
phosphorescence decay traces at 1270 nm after laser pulse employing 
a Peltier-cooled (- 62.8 ºC) Hamamatsu NIR detector operating at 650 
V, coupled to a computer-controlled grating monochromator. A pulsed 
Nd:YAG L52137 V LOTIS TII was used at the excitation wavelength of 
355 nm. The single pulses were of ca. 10 ns duration, and the energy 
was lower than 5 mJ per pulse. The system consisted of the pulsed laser, 
a 77250 Oriel mono-chromator coupled to the Hamamatsu NIR 
detector and the oscilloscope connected to the computer. The output 
signal was transferred from the oscilloscope to a personal computer. 
All measurements were made at room temperature, under air 
atmosphere, and using deuterated water at pH ca. 7.4 (1mM PB) as 
solvent in 10 × 10 mm2 quartz cells with a capacity of 4 mL. The 






Perinaphthenone in water (singlet oxygen quantum yield (φΔ) ca. 0.98) 
was used as standard to estimate φΔ of each compound by comparing 
the phosphorescence intensities at 1270 nm. The signal was obtained 
from the average of 50 laser shots. In this context, fresh samples were 
used each five laser shots to obtain the luminescence of singlet oxygen 



























In this doctoral thesis, new drugs, produgs and materials have been 
investigated, with special emphasis on fluoroquinolones, colchicine and 
chlorambuxcil as drugs, an aminomethylcoumarin derivative as 
phototriggers and two types of upconversion nanoparticles as part of 
new nanosystems. Thus, a thorough research work has been carried out 
to get a deeper insight into the photochemistry, photophysics and 
phototoxicity of mentioned systems. 
In this context, different strategies have been carried out to 
investigate new light-mediated cancer treatments. On one hand, a 
study on new phototoxic drugs, their characteristics under UVA light 
and using IR light of upconversion nanoparticles. On the other hand, 
synthesizing new nanosystems by combining new prodrugs formed by 
a photoremovable protecting group and different drugs with 
upconversion materials. Very different drugs were selected as object of 
study based on aforementioned strategies. The first were 
fluoroquinolones, generally used as antibacterial drugs, but with great 
photogenotoxic properties. As part of the prodrugs, colchicine, rarely 
used due to its high toxicity but with great properties and finally 
chlorambucil as a common anticancer drug.  
A study of new photogenotoxic fluoroquinolones and their 
photophysical, photochemical and phototoxic properties was 
performed in Chapter 3: 
• A new fluoroquinolone (1) with a N(1)-methyl group in the 






photodehalogenation process increasing the generation and 
lifetime an alkylating intermediate.  
• The highest phototoxicity of 1 in vitro 3T3 NRU assays was mainly 
attributed to the photodehalogenation process arising from its 
triplet excited state FQ. 
Next, the interaction between these new fluoroquinolones and 
others previously described such as Lomefloxacin and its acyl-
Lomefloxacin derivative with biomolecules and their phototoxic effects 
in cells have been analyzed in Chapter 4, assessing that: 
• N-alkyl chain at the position 1 of these fluoroquinolones is a small 
structural change that has a great influence in the interactions 
between FQ and biomolecules. 
• The phototoxic effect observed in the FQs of this study can be 
understood by combining the affinity of these compounds to 
biomolecules such as DNA and/or proteins with the reactivity of 
their photogenerated intermediates. 
Finally, for fluoroquinolones studies, design of a new material 
composed by best fluoroquinolone of previous chapters and 
upconversion nanoparticles was achieved: 
• New NaYF4: Yb/Tm (18%, 0,5%) @NaYF4 @1-SA material has been 
synthesized. 
• Improvement of the high phototoxic ability observed for 






Going to prodrugs strategies, first, synthesis of new prodrug 
composed by 7-amino-4-hydroymethylcoumarine chromophore (COU) 
as photoprotecting group and N-deacetylcolchicine (DCO) was done. 
However, photolysis of this dyad COU-DCO does not produce drug 
liberation. Photophysical studies were done to understand this 
unexpected result: 
• Photophysical and photochemical properties of COU can be clearly 
modified when a linked chromophore can generate electron 
transfer processes as evidenced with COU, COU-DCO and COU-
PHA. 
• The intermediate responsible of this type of electron transfer 
process but also the described photorelease reaction associated 
to coumarin derivatives was established.  
Finally, a new material based on a prodrug formed by the linking of 
a coumarin as phototrigger with chlorambucil as drug and an 
upconversion nanosystem was studied. As non toxic hydrophilic shell 
was selected Human Serum Albumin (HAS), which, at the same time, 
was the loading site for the prodrug:  
• An upconversion-based phototriggered drug-release system using 
HSA as biocompatible shell was synthesized.  
• The binding affinity of chemicals to HSA is a novel and easy method 
to prepare NIR light-responsive nanodrug delivery systems with 






























Cancer is one of the leading causes of death worldwide. Generally 
used anticancer treatments have various side effects produced by their 
low specificity. This is one of the reasons why the search for new 
treatments continues. 
Within these new investigations is the extensive field of 
nanomedicine, which can be explained as the study of new materials 
on a nanometric scale. It can be translated in the reduction of these 
side effects by increasing the selectivity and specificity of the 
treatments. Among the nanomaterials are upconversion nanoparticles 
that are capable of absorbing light in the near infrared and emit it in the 
ultraviolet-visible region. 
On the other hand, since the beginning of the history of medicine, 
light has been used as a form of treatment, having a very important 
role. A drawback for such treatments is sometimes the need to use light 
from the ultraviolet-visible region since biomolecules are capable of 
absorbing and causing cell damage. 
In this context, this Doctoral Thesis focuses on the study of new 
forms of anticancer treatment combining nanomedicine and light. For 
this, new phototoxic drugs and new materials capable of being 
activated by near infrared light have been developed. 
First, new fluoroquinolones were synthesized to explore their 






the Thesis). The photophysical and photochemical characteristics of the 
new compounds were studied, in addition to their ability to produce 
greater phototoxicity in cells than fluoroquinolones such as 
lomefloxacin by applying ultraviolet light. 
Based on the results obtained, a study was carried out to determine 
the differences between the interactions of some dihalogenated 
fluoroquinolones including the above commented, and biomolecules 
such as DNA and proteins. The reactivity of their photo-generated 
intermediates was also studied in Chapter 4. 
After a deep knowledge of the phototoxic capacity of the new 
drugs, design of a nanosystem composed of fluoroquinolones and 
upconversion nanoparticles was carried out in Chapter 5. The high 
phototoxic capacity of this new nanosystem was demonstrated. In this 
way phototoxic activity was generated from a fluoroquinolone without 
the use of ultraviolet light. 
On the other hand, the formation of prodrugs opens a door to the 
selective administration of anticancer drugs. Prodrugs consist of the 
photolabile binding of a molecule capable of being activated by light 
and the drug of interest.  However, a knowledge of the photophysical 
and photochemical properties of the phototrigger as well as the redox 
potentials of both members of the dyad can be crucial to obtain the 
desired photorelease. Thus, in Chapter 6, the relevance of these data 
was highlighted using a prodrug formed by a coumarin derivative as a 






Finally, in Chapter 7 the synthesis of a new nanosystem containing 
a prodrug  formed by a derivative of coumarin  linked to the anticancer 
drug  chlorambucil, and upconversion biocompatible nanoparticles  
was explored. The addition of human serum albumin as a coating for 
the nanoparticles fulfills the dual function of obtaining biocompatible 







El cáncer es una de las principales causas de muerte a nivel mundial. 
Los tratamientos anticancerígenos generalmente usados tienen 
diversos efectos secundarios producidos por su baja especificidad. Esta 
es una de las razones por las que se sigue en continua búsqueda de 
nuevos tratamientos. 
Dentro de estas nuevas investigaciones se encuentra el extenso 
campo de la nanomedicina, es decir, el estudio de nuevos materiales a 
escala nanométrica. Esta permite reducir dichos efectos secundarios 
aumentando la selectividad y especificidad de los tratamientos. Dentro 
de los nanomateriales se encuentran las nanopartículas de 
upconversion que son capaces de absorber luz en el infrarrojo cercano 
y emitirla en la región ultravioleta-visible. 
Por otro lado, desde el principio de la historia de la medicina la luz 
se ha empleado como forma de tratamiento teniendo un rol muy 
importante. Un inconveniente para dichos tratamientos suele ser la 
necesidad de emplear luz de la región ultravioleta-visible, pues las 
biomoléculas son capaces de absorber y produce daño celular.  
En este contexto, la presente Tesis Doctoral se centra en el estudio 
de nuevas formas de tratamiento anticancerígeno combinando 
nanomedicina y luz. Para ello se han desarrollado nuevos fármacos 
fototóxicos y nuevos materiales capaces de ser activados mediante luz 






En primer lugar, se sintetizaron nuevas fluoroquinolonas para 
explorar sus propiedades fototóxicas para su uso en fotoquimioterapia 
(Capítulo 3 de la Tesis). Se estudiaron las características fotofísicas y 
fotoquímicas de los nuevos compuestos, además de su capacidad para 
producir mayor fototoxicidad en las células en comparación con las 
fluoroquinolonas como la lomefloxacina mediante la aplicación de luz 
ultravioleta.  
En base a los resultados obtenidos se realizó un estudio para 
determinar las diferencias entre las interacciones de algunas 
fluoroquinolonas dihalogenadas, incluidas las comentadas 
anteriormente, y biomoléculas como ADN y proteínas. La reactividad 
de sus intermedios fotogenerados también se estudió en el Capítulo 4. 
Tras conocer en profundidad la capacidad fototóxica de los nuevos 
fármacos, en el Capítulo 5 se llevó a cabo el diseño de un nanosistema 
compuesto por fluoroquinolonas y nanopartículas de conversión 
ascendente. Se demostró la alta capacidad fototóxica de este nuevo 
nanosistema. De esta manera, se generó actividad fototóxica a partir 
de una fluoroquinolona sin el uso de luz ultravioleta 
Por otro lado, la formación de profármacos abre la puerta a la 
administración selectiva de fármacos contra el cáncer. Los profármacos 
consisten en la unión fotolábil de una molécula capaz de ser activada 
por la luz y el fármaco de interés. Sin embargo, un conocimiento 
profundo de las propiedades fotofísicas y fotoquímicas del 






diada puede ser crucial para obtener la fotoliberación deseada. Así, en 
el capítulo 6, se destacó la relevancia de estos datos utilizando un 
profármaco formado por un derivado de cumarina como molécula 
fotoactivable y colchicina como fármaco. 
Finalmente, en el Capítulo 7 se exploró la síntesis de un nuevo 
nanosistema que contiene un profármaco formado por un derivado de 
cumarina unido al fármaco contra el cáncer clorambucilo y 
nanopartículas biocomatibles de conversión ascendente. La adición de 
albúmina de suero humano como recubrimiento de las nanopartículas 
cumple la doble función de obtener nanopartículas biocompatibles y 








El càncer és una de les principals causes de mort a nivell mundial. 
Els tractaments anticancerígens generalment usats tenen diversos 
efectes secundaris produïts per la seva baixa especificitat. Aquesta és 
una de les raons per les que se segueix en contínua recerca de nous 
tractaments. 
Dins d'aquestes noves investigacions es troba l'extens camp de la 
nanomedicina, és a dir, l'estudi de nous materials a escala nanomètrica. 
Aquesta permet reduir aquests efectes secundaris augmentant la 
selectivitat i especificitat dels tractaments. Dins dels nanomaterials es 
troben les nanopartícules de upconversion que són capaços d'absorbir 
llum en l’infraroig proper i emetre-la en la regió ultraviolada-visible. 
D'altra banda, des del principi de la història de la medicina la llum 
s'ha emprat com a forma de tractament tenint un paper molt 
important. Un inconvenient per aquests tractaments sol ser la 
necessitat d'emprar llum de la regió ultraviolada-visible, ja que les 
biomolècules són capaços d'absorbir-la i produïr dany cel·lular. 
En aquest context, la present Tesi Doctoral es centra en l'estudi de 
noves formes de tractament anticancerigen combinant nanomedicina i 
llum. Per això s'han desenvolupat nous fàrmacs fototòxics i nous 
materials capaços de ser activats mitjançant llum infraroja propera. 
En primer lloc, es van sintetitzar noves fluoroquinolones per 






fotoquimioteràpia (Capítol 3 de la Tesi). Es van estudiar les 
característiques fotofísiques i fotoquímiques dels nous compostos, a 
més de la seva capacitat per produir major fototoxicitat en les cèl·lules 
en comparació amb les fluoroquinolones com la lomefloxacina 
mitjançant l'aplicació de llum ultraviolada. 
En base als resultats obtinguts es va realitzar un estudi per 
determinar les diferències entre les interaccions d'algunes 
fluoroquinolones dihalogenades, incloses les comentades 
anteriorment, i biomolècules com ADN i proteïnes. La reactivitat de les 
seves intermedis fotogenerats també es va estudiar en el Capítol 4. 
Després de conèixer en profunditat la capacitat fototòxica dels nous 
fàrmacs, en el Capítol 5 es va dur a terme el disseny d'un nanosistema 
compost per fluoroquinolones i nanopartícules de upconversion. Es va 
demostrar l'alta capacitat fototòxica d'aquest nou nanosistema. 
D'aquesta manera, es va generar activitat fototòxica a partir d'una 
fluoroquinolona sense l'ús de llum ultraviolada 
D'altra banda, la formació de profàrmacs obre la porta a 
l'administració selectiva de fàrmacs contra el càncer. Els profàrmacs 
consisteixen en la unió fotolábil d'una molècula capaç de ser activada 
per la llum i el fàrmac d'interès. No obstant això, un coneixement 
profund de les propietats fotofísiques i fotoquímiques del 
fotodisparador i dels potencials redox de tots dos membres de la diada 
pot ser crucial per obtenir el fotoalliberament desitjada. Així, en el 






profàrmac format per un derivat de cumarina com a molècula 
fotoactivable i colquicina com a fàrmac. 
Finalment, en el Capítol 7 es va explorar la síntesi d'un nou 
nanosistema que conté un profàrmac format per un derivat de 
cumarina unit a l'fàrmac contra el càncer clorambucilo i nanopartícules 
biocomatibles de upconversion. L'addició d'albúmina de sèrum humà 
com a recobriment de les nanopartícules compleix la doble funció 
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